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ABSTRACT
Inherited metabolic diseases (IMDs) of the liver have a collective occurrence of
about 1 in 800 births. Current therapies for IMDs of the liver are limited, and the only
curative option for patients is orthotopic liver transplantation. Due to shortages of organ
donors, immunosuppression following the transplantation, and mortality risks associated
with the procedure, alternative treatment options are necessary for curing IMDs of the
liver. Therapeutic gene editing has been proposed as a potential strategy for treating
IMDs of the liver. Adeno-associated viral vectors (AAVs) are the most widely used
delivery method for liver-targeted gene therapies. Although widely used for gene editing,
AAV vectors can integrate into the host genome, causing mutagenesis and prompting an
immune response. Non-viral methods for delivering gene editing tools would avoid safety
risks associated with AAV vectors. This research investigated two methods for delivering
CRISPR-Cas9 into primary hepatocytes: electroporation and lipid nanoparticles.
As proof-of-principle for our therapeutic approach, we designed CRISPR-Cas9
targeting hydroxyphenylpyruvate dioxygenase (Hpd), a therapeutic target for hereditary
tyrosinemia type I. We delivered Hpd- targeting CRISPR-Cas9 as plasmid DNA, mRNA,
and ribonucleoproteins (RNPs) and compared the on and off-target Cas9 editing
efficiencies. We achieved high levels of on-target editing in freshly isolated primary
mouse hepatocytes. We observed that hepatocytes treated with Cas9 mRNA had reduced
on-target editing compared to hepatocytes treated with Cas9 RNP. Human hepatocytes
electroporated with Cas9 RNPs also showed high levels of gene editing (>50%). We then
compared unmodified and chemically modified sgRNAs and found that in hepatocytes

ii

the sgRNA does not need to be chemically modified for Cas9 to achieve high levels of
on-target editing.
We also examined the off-target editing in primary mouse hepatocytes
electroporated with our Hpd-aiming CRISPR-Cas9. Ten potential off-target sites were
identified in the mouse genome with sequences containing up to 3 mismatches to the
gRNA sequence. Next-generation sequencing was used to quantify editing at these
potential off-target sites. We identified one site (OF3) that had high levels of off-target
editing (>20%). We electroporated hepatocytes with a high-fidelity variant of Cas9 (HiFi
Cas9) and observed reduced off-target editing.
Next, we delivered CRISPR-Cas9 into hepatocytes by chalcogen-containing lipid
nanoparticles (LNPs). We screened different LNP formulations by delivering eGFP
mRNA into Hepa 1-6 and HEK293 cells and identified three LNP formulations that
provided high transfection efficiency in cells. We next optimized LNP transfection
parameters in primary mouse hepatocytes that provided transfection efficiency of up to
45% and cell viability greater than 60%.
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CHAPTER ONE
INTRODUCTION
Inherited metabolic diseases (IMDs) of the liver are genetic disorders typically
characterized by an enzyme deficiency in a critical metabolic pathway. Substrates can
accumulate in the absence of an essential enzyme, leading to toxicity. IMDs occur in
roughly 1 in 800 births1 and can lead to organ failure or premature death if not treated2,3.
Hereditary tyrosinemia type 1 (HT1) is associated with loss-of-function mutations in the
gene encoding fumarylacetoacetate hydrolase (FAH). This enzyme processes the final
step in the tyrosine catabolism pathway to convert fumarylacetoacetate into non-toxic
metabolites. Without treatment, patients with HT1 suffer from liver toxicity and have an
increased risk of developing hepatocellular carcinoma as early as infancy4,5. The only
curative option for patients with HT1 is orthotopic liver transplantation, but it is limited
by donor shortages and complications from life-long immunosuppressive therapy
following the procedure. The standard treatment option for HT1 is an oral drug
nitisinone, also known as NTBC, that reprograms the tyrosine catabolism pathway by
inhibiting 4-hydroxyphenylpyruvate dioxygenase (HPD), an enzyme upstream in the
tyrosine catabolism pathway, to prevent the formation of toxic metabolites6. Although
NTBC in conjunction with a tyrosine-restricted diet is the first-line treatment for HT1,
not all patients respond well to treatment7. Side effects, such as nausea and blurred
vision, and patient compliance are also obstacles for this treatment7. Long-term studies
have also shown that patients on NTBC are still at a higher risk for developing liver
cirrhosis, HCC, and having impaired intellectual development8–10.
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Liver-directed gene editing is a promising therapeutic option for IMDs. The
discovery of clustered regularly interspaced short palindromic repeats (CRISPR) and
CRISPR-associated protein (Cas9) nucleases have made it possible to alter sequences in
the genome by introducing a double-stranded break at a target sequence. A novel
treatment strategy for HT1 is to use CRISPR-Cas9 to introduce a frameshift mutation in
HPD and disrupt the gene and tyrosine catabolism pathway before toxic metabolites are
produced. However, a significant barrier to applying Cas9 for therapeutic gene editing is
the delivery of CRISPR-Cas9 into target cells. The standard delivery method for Cas9directed gene editing is to use adeno-associated viral vectors (AAVs), which have been
used to correct animal models of human IMDs11–13. However, AAVs are associated with
safety concerns such as insertional mutagenesis and immune response to vectors14–16.
Nonviral ex vivo Cas9 gene editing is potentially safer for delivery as it reduces
immunogenicity risks and limits Cas9 editing to target cells. The goal of this research is
to characterize nonviral methods for delivering CRISPR-Cas9 into primary hepatocytes
for gene editing.
This dissertation research demonstrates that CRISPR-Cas9 can be delivered into
primary mouse and human hepatocytes and generate high levels of on-target editing by
electroporation. Next, we quantify the levels of off-target editing by CRISPR-Cas9 using
our sgRNA targeting mouse Hpd using next-generation sequencing. Lastly, we
demonstrate that Cas9 can be delivered into mouse and human hepatocytes by lipid
nanoparticle (LNP)-mediated delivery.
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Specific Aims
Aim 1: Optimize electroporation-mediated delivery of HPD-targeting CRISPR-Cas9 into
liver-derived cells and primary hepatocytes.
a. Design guide RNAs and validate CRISPR-Cas9 targeting the mouse Hpd and
human HPD.
b. Evaluate the efficiency of Hpd-aiming CRISPR-Cas9 delivered as different
forms in Hepa 1-6 cells.
c. Evaluate the effects of CRISPR-Cas9 mediated gene editing on efficiency and
cell functionality in primary mouse and human hepatocytes.
Aim 2: Evaluate if chemically modified sgRNAs improve efficacy and mutant Cas9
enhance the specificity of gene editing in primary mouse hepatocytes.
a. Evaluate chemical modifications in the sugar-phosphate backbone in synthetic
sgRNA on Cas9 efficiency in Hepa1-6 cells and primary mouse hepatocytes.
b. Develop a pipeline for rhAmpSeq analysis of Cas9 specificity and apply it for
evaluating the extent to which high-fidelity Cas9 retains efficiency while
reducing off-target gene editing.
Aim 3: Optimize lipid nanoparticle-mediated delivery of CRISPR-Cas9 into liverderived cells and primary hepatocytes.
a. Screening different formulations of lipid nanoparticles for efficient delivery
into liver-derived cells and primary hepatocytes
b. Optimize transfection parameters in primary mouse hepatocytes using eGFP
mRNA-LNPs.
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c. Evaluate LNP-mediated delivery of CRISPR-Cas9 mRNA into Hepa 1-6 for
gene editing and evaluate cell viability and functionality.
Research Strategy
Significance
IMDs of the liver result in the deficiency of hepatic enzymes essential for
metabolic pathways. The blockage of a metabolic pathway can lead to the accumulation
of toxic metabolites3. Without treatment, some of these diseases, such as HT1 and
familial hypercholesterolemia, can be fatal. The only curative option for patients with an
IMD is liver transplantation. However, this option is limited by shortages of donor
organs, high-risk mortality from the procedure, and the requirement for life-long
immunosuppression therapy17,18. Because of the limitations of current methods for curing
IMDs of the liver, alternative strategies are needed for patients with IMDs.
Gene editing offers a potentially curative and permanent option that bypasses the
limitations of the current methods for treatment for IMDs. CRISPR-Cas9 is a versatile
tool for gene editing and composed of a chimeric guide RNA (sgRNA) that contains a
20-nucleotide sequence complementary to a target site and a Cas9 protein. The sgRNA
guides the Cas9 protein to a target site where the Cas9 protein generates a doublestranded break (DSB)19. The DSB can be repaired by either the nonhomology end joining
(NHEJ) pathway or homology-directed repair (HDR)20. During NHEJ, the separated
DNA strands are annealed together, resulting in the insertion or deletion of nucleotides at
the break site. The insertion and deletion of nucleotides referred to as indels can lead to
frameshifts to disrupt gene expression21.
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A novel gene editing therapeutic strategy for HTI involves knocking down HPD
to prevent the accumulation of toxic metabolites such as fumarylacetoacetate (FAA),
maleylacetoacetate (MAA), succinylacetoacetate (SAA), and succinylacetone (SA).
CRISPR-Cas9 mediated gene-editing has been demonstrated to correct IMDs of the liver
in preclinical studies using mice12,13,22. These trials delivered Cas9 into mice by adenoassociated viral vectors (AAVs). Viral vectors are currently the standard approach for
delivering gene-editing reagents into cells but are associated with risks limiting their
application in clinical studies. Preclinical studies have found that AAVs can randomly
insert into the genome14,15 and potentially induce hepatocellular carcinomas23.
Preexisting immunity to Cas9 is another obstacle for in vivo viral strategies to
deliver Cas9. The most widely used Cas9 protein for gene editing, SpCas9, is derived
from Streptococcus pyogenes24, a bacterium that frequently infects human populations. A
human serum study observed that 58% of donors expressed antibodies against SpCas9
and found anti-SpCas9 T cells in 67% of donors25. Another study found that 96% of the
sample population tested expressed Cas9 specific T-cells26. A preclinical study found that
viral delivery of Cas9 to mice with preexisting immunity to Cas9 resulted in the
elimination of genetically modified cells in the liver following an increased T cell
response27. In that study, mice were exposed to the Cas9 protein before transduction.
AAV vectors containing a Cas9 transgene were then injected into the immunized mice.
One week after transduction, treated mice were observed to have an increased presence of
CD8+ cytotoxic T cells in the liver. Twelve weeks after transduction, researchers
observed that nearly all the gene-edited cells had been eliminated from the liver. The

5

immune response was activated by the presence of Cas9 peptides on major
histocompatibility complex (MHC) class I molecules on the treated cells. Cells treated in
vivo using AAVs to deliver the CRISPR-Cas9 system are therefore vulnerable to being
eliminated by an immune response.
To avoid elimination by an immune response, CRISPR-Cas9 could be delivered
ex vivo, and target cells can then be cultured until they no longer express Cas9 peptides
on MHC class I molecules. In addition, ex vivo delivery of CRISPR-Cas9 reagents
provides an opportunity to screen target cells before transplantation to confirm successful
gene editing and expand gene-edited cells to improve the possibility of engraftment. Ex
vivo strategies also allow for the delivery of more transient forms of Cas9, such as
ribonucleoproteins (RNPs) consisting of Cas9 protein complexed with synthetic sgRNA.
Gene editing by transient expression of Cas9 such as mRNA or RNP is associated with
reduced off-target editing compared to stable Cas9 expression by plasmid DNA28.
The proposed research is to develop a nonviral strategy for introducing Cas9 into
hepatocytes for therapeutic gene editing of HT1. The delivery techniques studied will be
nonviral approaches: electroporation and LNPs. In contrast to viral delivery approaches,
electroporation and LNPs do not carry risks for insertional mutagenesis and are not
associated with preexisting immunity. Research into nonviral delivery of Cas9 into
hepatocytes is limited, so the proposed study will evaluate the efficacy and toxicity of
nonviral delivery to hepatocytes.
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Innovation
There are currently no approved methods for treating IMDs of the liver by gene
therapy. The lack of safe and effective means for delivering Cas9 into hepatocytes is a
significant barrier to translating this technology into clinical application. This study’s
innovation comes from being the first to investigate nonviral methods for ex vivo
delivery of CRISPR-Cas9 components into hepatocytes for therapeutic gene editing. No
other study has evaluated this strategy leaving a gap in the literature. This research will
assess if electroporation- and LNP-mediated delivery of Cas9 are feasible strategies for
achieving efficient gene editing in hepatocytes. We propose to evaluate the efficacy and
specificity of Cas9 gene editing delivered into hepatocytes by electroporation and lipid
nanoparticles. We will also assess each strategy’s potential toxicity for hepatocytes. This
study will determine the optimal conditions for electroporation of primary human
hepatocytes with Cas9 laying the foundation for future clinical work.
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CHAPTER TWO
A REVIEW OF THE LITERATURE
2.1 Hereditary Tyrosinemia Type 1
2.1.1 Hereditary Tyrosinemia Type 1 Pathology
The liver is a crucial organ and the site of multiple metabolic pathways. The
primary cell type that carries out the liver’s metabolic functions are hepatocytes.
Hepatocyte metabolic activity can be impaired by numerous genetic diseases. Inherited
metabolic diseases (IMDs) of the liver are a large class of genetic disorders characterized
by a deficiency of an essential enzyme necessary for metabolic pathways. The loss of
these crucial proteins can result in the accumulation of toxic byproducts leading to organ
failure of premature death1,2. IMDs are typically autosomal recessive conditions caused
by a single gene mutation. Around 700 diseases have been identified as IMDs3
Individually, IMDs are rare, but collectively they have an occurrence rate of 1 in 800
births3. The only curative therapy for IMDs of the liver is an orthotopic liver
transplantation. However, liver transplantation is not considered a viable treatment for all
patients because of organ shortages, life-long immunosuppression following the
procedure, and the high mortality risk associated with the surgery.
Hereditary Tyrosinemia type 1 (HT1) is an IMD of the liver that prevents the
catabolism of tyrosine. HT1 is caused by a recessive mutation in the FAH gene leading to
a deficiency of fumarylacetoacetate hydrolase (FAH), the last enzyme in the tyrosine
catabolism pathway. Without FAH, the substrate fumarylacetoacetate (FAA) cannot be
converted into fumarate and acetoacetate. This leads to the accumulation of toxic
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metabolites such as FAA, maleylacetoacetate (MAA), succinylacetoacetate (SAA), and
succinylacetone (SA). These toxic metabolites can cause severe liver, kidney, and neural
damage. FAA and MAA can cause genomic instability, putting patients at severe risk for
developing hepatocellular carcinomas (HCCs)4. Symptoms for HT1 include liver
damage, failure to gain weight in infancy, reduced coagulation factors, hypoglycemia,
hepatomegaly, and jaundice. Patients with HT1 are at high risk for liver, renal
dysfunction and development of HCCs. Symptoms generally appear in infancy, with
most patients displaying acute liver failure and renal dysfunction before six months old if
left untreated5,6.
2.1.2 Current Treatment Options
Standard treatment for patients with HT1 is a combination of 2-(2-nitro-4trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), also known as nitisinone, taken
in combination with a tyrosine-restricted diet7. However, compliance with the diet and
drug is a significant obstacle for treatment8. Orthotopic liver transplantation is the only
curative measure for HT1 but is a limited option. Lack of donor organs, complications
such as liver rejection, and increased risk for infection due to immunosuppression prevent
widespread use of liver transplants to treat HT19,10. In 1992, a third treatment option was
introduced when Lindstedt et al. demonstrated that administration of the oral drug NTBC
prevented the production of SAA and SA and improved liver function11 NTBC inhibits
the enzyme HPD at an early stage in the tyrosine catabolism pathway and prevents the
buildup of toxic metabolites (Figure 2.1). Treatment with NTBC successfully ameliorates
liver and renal damage. However, NTBC is not an ideal treatment as patients are still at a
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higher risk for developing liver cirrhosis, HCC, and having impaired intellectual
development12–15. In addition, patient compliance with taking an oral drug daily hinders
this treatment.

Figure 2.1 Tyrosine catabolism pathway. Patients with HT1 lack sufficient FAH to
break down fumarylacetoacetate and malelylacetoacetate. Treatment with NTBC
prevents the pathway from proceeding to the formation of toxic metabolites16.
The lack of available curative treatments for HT1 motivated the development of
gene therapies to treat HT1. HT1 is an ideal candidate for gene therapy because the
disease is caused by a single mutated gene17, and gene-corrected hepatocytes will have a
competitive advantage over diseased cells to repopulate the liver.
2.2 Gene Therapy for Treatment of IMDs of the Liver
2.2.1 Conventional Gene Therapy for Treatment of Liver Disease
Before the discovery and implementation of nucleases for therapeutic gene
editing, gene therapies delivered transgenes to diseased cells by a gene vector. The
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standard strategy for conventional gene therapy is to deliver a therapeutic transgene into
cells in vivo by viral vectors. This strategy has been investigated in preclinical and
clinical settings to restore expression of clotting factor FIX in hepatocytes to treat
hemophilia B. Preclinical trials have used adeno-associated viral (AAV) vectors to
successfully increase expression of clotting factor IX (FIX) and diminish symptoms in
mouse and dog models of hemophilia B18,19.
In clinical trials, AAV delivery of transgenes into the liver has been less
successful. In one clinical trial for patients with severe hemophilia B, patients were
treated with an AAV vector-based on AAV serotype 2 containing the F9 transgene to
promote expression of FIX clotting factor 20. In the week following treatment, researchers
observed that FIX expression levels in patients rose to ~10% of FIX expression in healthy
individuals20. Five weeks after treatment, FIX expression began to decline, and
expression returned to pretreatment levels by ten weeks. Loss of FIX expression was
attributed to the removal of AAV capsids by the immune system. A later clinical trial
used an alternative AAV, AAV8, to deliver F9 to ten patients with hemophilia B21. FIX
expression in treated patients rose to 1-6% of normal levels. Bleeding episodes associated
with hemophilia were reduced but not eliminated21. Increased FIX expression lasted
significantly longer, with a follow-up study observing stable expression eight years after
treatment22. Increased levels of anti-AAV8 IgG were also observed in treated patients,
and the authors noted that this could be a barrier to repeated treatment if FIX levels
decreased.
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Similar therapies have been attempted with adenoviral vectors; however, safety
concerns have limited the adoption of this strategy to treat liver disease. In 1999 a livertargeted gene therapy trial attempted to treat partial ornithine carbamylase deficiency
(OTCD) by transducing patients with an adenovirus type 5 vector containing human OTC
cDNA23. Unfortunately, one patient treated with the adenovirus suffered from severe
inflammatory response, leading to organ failure and death following treatment. This
occurred despite preclinical trials in mice and nonhuman primates indicating that
adenovirus-mediated gene transfer of OTC had an acceptable safety profile24,25. In
addition to safety concerns, clinical trials using standard gene therapy found moderate to
no improvement in patients22,26. Because of the limitations observed in clinical trials with
standard gene therapy, current strategies for treating IMDs of the liver have switched to
gene editing approaches.
2.2.2 Nuclease Mediated Gene Therapy for Treatment of Liver Disease
Gene editing is a type of gene therapy that treats disease by altering an organism’s
genome at a specific locus27. Gene editing requires a tool capable of binding to a target
sequence of DNA and then inducing a double-strand break (DSB) near the target site.
Cleavage of DNA activates the cellular DNA repair pathways, which include nonhomologous end joining (NHEJ) and homology-directed repair (HDR) (Figure 2.2). The
more active pathway, NHEJ, ligates broken strands of DNA together without a repair
template. This method is highly susceptible to generating nucleotide insertions or
deletions (indels) at the break site. Indels can potentially cause gene knockout by creating
a frameshift mutation. However, indels are not a guaranteed outcome of NHEJ. The HDR
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pathway is less error prone than NHEJ when mending DSBs. This pathway requires a
DNA template with homology to the sequences adjacent to the break site. Donor
constructs can be delivered into cells and used to introduce specific mutations into the
genome. This pathway occurs only in the late S and G2 cell cycles and is less active than
NHEJ. Before the widespread adoption of CRISPR-Cas9, genome editing was typically
performed with zinc-finger nucleases (ZFNs) and transcription activator-like effector
nucleases (TALENs).

Figure 2.2. Pathways for repairing DSBs. DSBs generated by nucleases can be repaired by
either NHEJ or HDR. NHEJ is more error-prone but highly active, while HDR is precise
but less efficient28.
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The ZFN structure consists of a DNA-binding domain and a DNA-cleaving
domain. These proteins typically have a structure size of 30 amino acids and contain a
type II restriction endonuclease domain called the FokI capable of cleaving DNA. The
endonuclease domain is bound to zinc finger domains that recognize and bind to a DNA
sequence composed of 3 or 4 base pairs. Zinc finger domains can be engineered to target
different sites by combining other zinc finger domains to be complementary to a
sequence of 18-36 bps. Because ZFNs dimerize before cleaving DNA, two ZFNs must
bind to the DNA within 5-7 base pairs on opposite strands of DNA. ZFNs have been
studied for different strategies to treat IMDs of the liver. One approach is to edit genes of
stem cells with ZFNs, differentiate the cells into hepatocyte-like cells, and then transplant
them into the liver. In vitro studies have shown that ZFNs can be used in human induced
pluripotent stem cells (iSPCs) derived from liver cells to correct a point mutation in
SERPINA1 responsible for α1-antitrypsin deficiency (AATD)29. Another strategy is to
deliver ZFNs in vivo to edit liver cells and restore the expression of a lost protein. This
strategy was demonstrated to restore human factors VIII and IX expression to therapeutic
levels in vivo in mouse models of hemophilia A and B30. LNP delivery of mRNA ZFNs
has knocked out the expression of Pcsk9 successfully at high levels with a 90% reduction
of protein expression31.
TALENs are formed by the binding of the catalytic domain of the endonuclease
FokI with a TALE DNA-binding domain32. The TALE DNA-binding domain contains
highly conserved repeat sequences comprised of 33-35 amino acid residues. Two of these
residues, located at positions 12 and 13, are highly variable. These repeat variable
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diresidues (RVDs) determine nucleotide recognition. Like ZFNs, TALENs require two
constructs bound to opposite strands of DNA to generate DSBs at the target site.
Compared to ZFNs, TALENs have a broader targeting range32. In vitro editing of iSPCs
by TALENs has been used to create a cell model of hemophilia A by cleaving a section
of the F8 gene33. The study’s authors also demonstrated that TALENs could be used to
reverse the edit made, suggesting a potential strategy for treating hemophilia A with
genetically modified hiSPCs. TALENs have been investigated for treating a mouse model
of the IMD, arginase-1 deficiency34. TALENs were designed to reincorporate missing
exons in Arg1 and restore the expression of functioning arginase-1. The team transfected
iSPCs with the TALENs and differentiated the stem cells into hepatocyte-like cells. PCR
confirmed successful restoration of Arg1 expression. However, after transplantation, the
gene-corrected hepatocytes failed to repopulate the liver and only provided minimal
therapeutic effect.
2.3. CRISPR-Cas Mediated Gene Editing for Liver Disease
2.3.1 CRISPR-Cas9 Nucleases
The discovery of the CRISPR-Cas9 system has overshadowed the use of TALENs
and ZFNs for genome editing. CRISPR-Cas systems are RNA-guided nucleases adapted
from the bacterial immune response for genome editing35. CRISPR refers to a group of
small DNA sequences obtained from previous infections by viruses that bacteria
subsequently use as a defense mechanism against reinfection. About 3800 Cas proteins
have been discovered so far, but only a few have been demonstrated to perform gene
editing in human cells36. The most widely used CRISPR-Cas protein is the Cas9 nuclease
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adopted from Streptococcus pyogenes37. The CRISPR-Cas9 system is composed of a
Cas9 endonuclease and a 100-nucleotide single-guide RNA (sgRNA) that leads the Cas9
protein to a 20-nucleotide target site (Figure 2.3). The sgRNA is engineered by
combining a 20-nucleotide CRISPR RNA sequence complementary to the target site with
a transactivating CRISPR RNA, which acts as a binding scaffold for the nuclease. The
Cas9 protein is led to a target site by the sgRNA and then cleaves the DNA generating a
DSB. The break in the sequence activates the DNA repair pathways and allows for gene
editing by NHEJ or HDR. The only requirement for the target site is that a 5’-NGG
protospacer-adjacent motif (PAM) must be adjacent to the target site. The CRISPR-Cas9
system is a powerful editing tool and more versatile than other engineered nucleases.
Because ZFNs and TALENs bind to targets by protein-DNA interactions, DNA binding
domains must be engineered for different target sequences. As Cas9 binds to DNA by
RNA-DNA interactions, only the sgRNA must be modified to edit new targets38.
Comparison studies have demonstrated that Cas9 consistently provides higher gene
editing levels than ZFNs and TALENs39–42.
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Figure 2.3 Structure of CRISPR-Cas9 protein. The Cas9 system is composed of two
components: a 100 nucleotide sgRNA that directs the protein to a 20-nucleotide target
site and the Cas9 protein composed of RuvC and HNH nuclease domains which allow
for cleavage at the target site43.
CRISPR-based treatments for blood disorders and cancers are currently being
investigated in clinical trials. The first CRISPR clinical trial was for the treatment of βthalassemia and sickle cell anemia by ex vivo editing the patient’s HSCs to express fetal
hemoglobin and transplanting them back into the patient (NCT03655678). Initial results
of the phase 1/2 trial showed patients had hemoglobin levels in the normal range nine
months following the treatment44,45. A clinical trial in China performed ex vivo editing
with Cas9 on hematopoietic stem and progenitor cells (HSPCs) to confer HIV resistance
by knocking out CCR5. The CCR5-depleted cells were then transplanted to a patient with
HIV and acute lymphoblastic leukemia (NCT03164135). The genetically modified cells
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persisted for at least 19 months following treatment, but only 5% of CD4+ T-cells were
negative for CCR5 expression46. Ex vivo correction of diseased cells has demonstrated
promising results in the clinical setting but requires more research into the expansion of
transplanted genetically modified cells. Other clinical trials have used ex vivo CRISPRmodified T cells to improve anti-tumor activity. These trials include patients with
refractory B-cell malignancies (NCT04035434) and refractory multiple myeloma
(NCT04244656). Results have not yet been published for either study. The first in vivo
clinical trial with CRISPR-Cas9 delivered Cas9 mRNA into patients to treat transthyretin
amyloidosis (NCT04601051). Patients were injected with lipid nanoparticles complexed
to Cas9 mRNA to knockout TTR in liver tissue. Authors reported that TTR in the serum
was reduced by as much as 87% in treated patients with no adverse events were
reported47. A second in vivo clinical trial for CRISPR-Cas9 delivers the Cas9 gene by
AAV vector into the retina of patients for treatment of Leber Congenital Amaurosis Type
1 (NCT03872479).
At present, CRISPR-based treatments for HT1 and many other IMDs of the liver
have not yet been explored in clinical trials. Strategies proposed for treating metabolic
disorders of the liver by gene editing include in vivo delivery of Cas9 to diseased
hepatocytes by viral or nanoparticle delivery of Cas9, or isolation of diseased hepatocytes
for ex vivo gene correction with Cas9 and then autologous transplantation of the edited
cells48. A third strategy would be to derive iSPCs from the patient, perform genome
editing in vitro, and then differentiate the iSPCs into hepatocyte-like cells48. The
modified cells would then be transplanted back into the patient. However, iSPC to
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hepatocyte differentiation protocols typically produce cells more similar to fetal
hepatocytes than adult49. Preclinical studies have shown that these cells fail to repopulate
the liver after transplantation34. The major obstacles to clinical translation of CRISPRCas9 technology are safe and effective delivery methods for Cas9 and adverse events
from off-target Cas9 editing. The CRISPR-Cas9’s target domain will tolerate mismatches
of up to several base pairs allowing for binding and editing at sites like the target
sequences. Adverse events from Cas9 editing must be considered before using Cas9 for
therapeutic gene editing.
2.3.2 Base Editors
Base editing is a genome editing method that introduces precise point mutations
into the DNA or RNA of living cells without generating a DSB and without HDR50. Base
editors are formed from the fusion of a catalytically impaired CRISPR nuclease and a
single strand deaminase enzyme. The catalytically impaired nuclease binds to a target
sequence by a guide RNA but cannot create a DSB. Instead, the deaminase induces a
base conversion at the target site. The most widely used classes of base editors are
cytosine base editors (CBEs) and adenine base editors (ABEs) (Figure 2.4)51. Adenine
base editors mediate A•T-to-G•C conversions, while CBEs mediate C•G-to-T•A
conversions. More than 25% of human pathogenic SNPs could be corrected using ABEs
and CBEs52. Base editors allow precise editing that avoids the risks associated with
generating DSBs such as indel formation and cell cycle arrest from p53-mediated DNA
damage responses53. Because base editing avoids indel formation and does not require
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activation of the HDR pathway, it is an appealing alternative to CRISPR-Cas9 for
treating IMDs of the liver.

Figure 2.4 Mechanism for (A) Cytidine and (B) Adenosine base editors. Base editors
are composed of a dCas9 enzyme that introduces precise point mutations in the
genome54.
Although base editors have not reached clinical trials, preclinical trials seeking to
treat IMDs of the liver with base editors have had promising results. In Chadwick et al.,
the efficacy of in vivo base editing in the liver of mice was first established55. Adenoviral
vectors were used to deliver CBEs targeting Pcsk9 into mice to introduce nonsense
mutations in Pcsk9. In mice sacrificed five days after treatment, an average of 24% of
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base editing was observed, with low levels of indels also reported. These edits led to a
50% reduction in Pcsk9 and a nearly 30% reduction in plasma cholesterol levels. Adenine
base editors have been used to rescue a mouse model of HT1 by correcting the mutated
Fah gene56. In the mouse model for HT1, loss of Fah is caused by a homozygous G•C to
A•T point mutation in exon 8 of Fah. Editing efficiencies of close to 10% were observed
at the target site, and rapid expansion of gene-corrected cells allowed mice to become
independent of NTBC. Low levels of base editing were also observed at other positions
in the Fah locus. Base editors have also been used to correct mouse models of
phenylketonuria. Base editors have advanced to being used in preclinical trials in
nonhuman primates. In two studies published in 2021, adenine base editors were
delivered to the livers of cynomolgus macaques by injection with lipid nanoparticles to
knock out PCKS9 and reduce LDL levels57,58. Adenine base editors were delivered to the
liver of adult macaques to knock out PCKS9 and reduce LDL levels58 The average
editing efficiency was 26%, notably lower than when delivered to mice, with an average
editing efficiency of 61%. No off-target edits were observed. Repeated administration of
the base editors did not improve editing efficiency, which the authors attributed to a
potential humoral immune response. The other study had higher rates of gene knockout,
reporting up to 90% editing efficiency and 60% reduction in LDL cholesterol57. The
reduction remained stable for at least eight months after treatment. After administration
of the LNPs, AST and ALT levels increased for two weeks after treatment but returned to
stable levels afterward.
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2.4 Viral Delivery of Cas9 for Treatment of Liver Disease
2.4.1 Adeno-Associated Viral Mediated Delivery of Cas9
Discovered in the mid-1960s as a cell culture contaminant, AAVs have become
one of the most widely studied vectors in gene therapy59,60. AAVs are replicant-defective
parvoviruses endemic to humans and nonhuman primates. AAVs are not associated with
any diseases and have low immunogenicity61,62. The AAV genome is approximately 4.7
kilobases (kb) and contains two genes, rep and cap. Inverted terminal repeat (ITR)
sequences are present at both ends of the single-stranded genome. These ITR sequences
are necessary for genome replication. Recombinant AAVs (rAAVs) are made by
removing the rep and cap genes, leaving only the ITR sequences. Without the rep
sequence, rAAVs have a much lower chance of integrating into the genome. Transgenes
can be packed into the vector and delivered into the cell nucleus. A transgene encoding
the sequence for production of CRISPR-Cas9 can be packaged into an AAV and
delivered into cells by transduction. Two AAV serotypes, AAV8 and AAV9, have been
shown to have high transduction levels in hepatocytes63–66. Although widely used in
preclinical studies, AAV-mediated delivery of Cas9 is associated with challenges that
prevent clinical translation. Limitations for AAV-mediated delivery include low
packaging size of the vector, immunity to AAVs from previous exposure, and insertional
mutagenesis.
One strategy for overcoming the low packaging size of the AAV vector is to
deliver the gene encoding for the Cas9 protein and the therapeutic transgene in separate
AAV vectors (Figure 2.5). This strategy was utilized in a study where newborn and adult
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mice with partial deficiency in ornithine transcarbamylase were treated with SaCas9 and
a template containing the corrected ornithine transcarbamylase (OTC) gene delivered by
AAV8 vectors67. Because of the small packaging capacity of the AAV vector, the gene
encoding the SaCas9 and the gene encoding for OTC had to be delivered in separate
AAV vectors. Sequencing liver tissue harvested from newborn mice found an average of
10% of hepatocytes carried wild-type OTC. This was sufficient for mice to survive on a
high protein diet which usually exacerbates the disease. The treated adult mice showed
lower levels of gene correction, and higher instances of large deletions in the genome
were observed. A 2021 study tested the dual delivery of AAV8 vectors in a rabbit model
of HT168. One vector carried the gene coding for SpCas9, and the other vector carried the
corrected Fah gene. The dual vectors were delivered into 15-day old rabbits by injection
at the ear vein. PCR analysis of DNA extracted from the rabbits found gene correction
efficiencies ranging from 0.90% to 3.71%. Despite low levels of gene correction, treated
rabbits matured to adulthood without NTBC treatment and substantial liver or kidney
damage. Another study tested six smaller Cas9 variants against the SpCas9 variant by
AAV delivery for knockout of Pcsk9 in mice. The study aimed to find a smaller Cas9
protein than the SpCas9 for effective gene editing delivered by AAVs69. It was reported
that Cas9 from Staphylococcus aureus (SaCas9) had comparable levels of editing in the
liver as the SpCas9. The authors observed up to 40% of hepatocytes had been genetically
modified, and there were significant reductions in cholesterol levels of the treated mice.
The authors also reported no detectable liver damage or signs of inflammation following
in the four weeks following treatment. Despite being small enough to package the SaCas9
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and the sgRNA, a second AAV vector would still be required for delivering a repair
template for HDR.

Figure 2.5 Different strategies for delivering CRISPR-Cas9 and other elements by
AAVs. Because of the small size of the vector, either multiple viral vectors must be
used for delivery, or smaller variants of Cas9 must be substituted for SpCas970.
Immunogenicity risks are another concern that must be considered when using
AAVs. Previous infection from the wild-type AAV can inhibit rAAV transduction by the
presence of neutralizing antibodies. Studies have shown in mice that previous exposure to
AAVs can lead to loss of transduced cells due to the host immune response20,71.
Epidemiological studies have found that 40-80% of the human population presents antiAAV antibodies72,73. Widespread previous exposure to AAVs presents a significant
obstacle for using AAVs to deliver Cas9 to treat IMDs of the liver. Integration of the
vector at locus associated with the cell cycle is another primary concern when using
AAVs. Several studies have reported that insertional mutagenesis of AAVs has led to
HCCs in mice74,75. In Chandler et al., it was reported that AAV insertion into the Rian

28

locus led to upregulation of the gene Rtl1, which increased expression associated with
HCCs75. Despite not being associated with severe hepatoxicity, a recent clinical trial
(NCT03199469) testing treatment of X-linked myotubular myopathy using AAV8
vectors observed high hepatotoxicity in treated patients, and the study was placed on hold
after the death of three children in the trial76,77. Thus, safety concerns remain a severe
obstacle for the clinical application of AAV vectors.
2.4.2 Adenoviral Mediated Delivery of Cas9
Adenoviral vectors (AdVs) have also been investigated as a potential delivery
vehicle for liver-targeted Cas9 gene therapy. Adenoviruses are linear double-stranded
DNA vectors that do not integrate into the host genome. Adenoviruses are responsible for
many “common cold” cases, and symptoms are usually mild. However, for
immunosuppressed individuals, adenoviruses can cause serious disease78. Adenoviral
vectors have been used to deliver Cas9 into the livers of mice to generate loss-of-function
mutations at the gene Pcsk9 to reduce LDL levels79. Three days after administration of
Pcsk9 targeting Cas9, liver tissue from the mice was harvested, and high levels of gene
editing were reported, with one mouse having greater than 50% edits. The treated mice
also had reduced HDL and LDL levels, with no significant toxicity observed. Adenoviral
vectors have also been used to deliver Cas9 nickase into a mouse model of HT180. Low
levels of gene correction were observed, with only about 0.1% of hepatocytes having
corrected Fah. As the Fah positive cells have a proliferative advantage over Fah negative
cells, this was sufficient for mice to be rescued after a period of cycling on- and offNTBC. Three months after administering AdVs, Fah positive hepatocytes composed 60%
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of the liver. The mice did not experience liver cirrhosis or other severe forms of liver
damage.
Immunogenicity is a significant obstacle to the adenoviral delivery of Cas9. In
Guan et al., the authors compared delivery of Cas9 by AdVs and hydrodynamic injection
for the treatment of a mouse model of hemophilia B81. Donor templates containing the
corrected F9 expression were delivered alongside Cas9. Delivery with AdVs initially
resulted in higher levels of cells containing corrected F9 than mice treated with
hydrodynamic injection. The mice treated with adenoviruses did not experience
therapeutic effects and were reported to suffer from severe hepatotoxicity. The authors
reported elevation of inflammatory cytokines in treated mice, which indicated that
immunogenicity to the viral vectors was responsible for lack of therapeutic effect81.
Another study identified hepatic damage in mouse livers after treatment with AdVs to
generate a mouse model of nonalcoholic steatohepatitis (NASH)82. The AdVs contained
Cas9 expression and sgRNA targeting Pten, a gene associated with NASH. Indels were
observed at rates of 14-22% in the mice treated with the AdVs. Fourth months after
treatment, mice infected with the adenoviral vectors showed symptoms consistent with
NASH. Examination of the serum at one week and two weeks after treatment found
elevated levels of ALT and AST indicating significant liver damage. At two weeks after
receiving AdVs, mice were found to have higher levels of inflammatory cytokines when
compared to the control mice. CD4+ and CD8+ T-cells were also identified in the liver
tissue of mice, indicating that AdVs lead to a significant immune response in the treated
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tissue. Immunogenicity remains an obstacle to the widespread application of AdVs for
disease treatment.
2.4.3 Lentiviral Mediated Delivery of Cas9
Lentiviral vectors (LVs) have been studied as an alternative to AAVs and AdVs
to deliver CRISPR-Cas9. Lentiviruses are a type of retrovirus and, like other retroviruses,
contain an RNA genome. Lentiviruses enter a cell by direct membrane fusion or receptormediated endocytosis. After transducing a cell, lentiviruses convert the RNA genome into
DNA by a viral enzyme called reverse transcriptase. The viral DNA is then integrated
into the host genome. Lentiviral vectors are an attractive tool for gene therapies.
Integration into the genome allows for long-term expression of the transgene. Like
AAVs, LVs can transduce dividing and non-dividing cells. Compared to AAVs, the
carrying capacity for LVs is larger at 8 kb. Another advantage of using LVs is that
tropism to specific tissues can be controlled by modifying the glycoprotein envelope83.
Because of these advantages, LVs have been investigated as potential candidates for
liver-targeted gene therapy.
Lentiviral vectors have been used to treat several animal models of HT184–86.
Mouse hepatocytes were isolated from Fah-/- and ex vivo treated with LVs containing
Cas9 expression and AAVs containing a donor template with the corrected Fah
expression84. The treated hepatocytes were transplanted into Fah-/- deficient mice, and the
mice were cycled on- and off- NTBC for six months. Around 100 days after treatment,
mice showed stable weight gain indicating successful engraftment and expansion of
corrected hepatocytes. Sequencing of harvested liver tissue confirmed a gene correction
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average of 21.7%. Two studies have examined the efficacy of ex vivo delivery of Cas9 by
lentiviral vectors in HT1 pig models85,86. In Hickey et al., partial liver resection was
performed on four Fah-/- pigs to isolate hepatocytes diseased hepatocytes85. Hepatocytes
were then transduced with lentiviral vectors containing Fah expression and a reporter
sodium-iodide sym-porter (Nis) gene. Autologous transplants were then performed with
the transduced hepatocytes, and the recipient pigs were cycled on and off NTBC
following the transplantation. Hepatectomies performed on two pigs 12 months after
transplantation found that Fah-corrected hepatocytes had repopulated nearly the entire
liver. The pigs were also independent of NTBC treatment and did not show severe
fibrosis85. In Kaiser et al., this procedure repeated, and it was observed that when Fah
corrected hepatocytes repopulated 20% of the liver, pigs were no longer required NTBC
treatment86. Neither study reported significant hepatotoxicity from LV delivery of Cas9.
Despite successes in preclinical trials, safety concerns still exist for LVs as
therapeutic gene-editing tools. Infection of cells by LVs can activate oncogenes or
inactivate tumor suppressor genes87. Another mechanism that could promote cancer
formation is insertional mutagenesis of the vector into a transcriptional unit87. The risk of
the oncogenic potential of LVs increases when used to transduce dividing cells87. LVs
derived from HIV could also become a replication-competent virus with restored
pathogenicity by recombination87. Recent generations of LVs have had virulent genes
removed to mitigate risks if the vector becomes a replication-competent virus. These
designs, however, do not eliminate the risk of insertional mutagenesis87. Further LV
modifications are necessary to reduce their oncogenic potential.
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2.5 Nonviral Delivery of Cas9 for Treatment of Liver Disease
2.5.1 Electroporation-mediated Delivery of Cas9
Electroporation is a physical method of transfection that applies pulses of highvoltage currents to initiate the opening of pores in the cell membrane (Figure 2.6). Gene
editing reagents can then enter cells through these transient pores. Electroporationmediated delivery of genetic material was first demonstrated in 1982 when plasmid DNA
was delivered to mouse L cells88. Electroporation efficiently delivers cargo into many cell
types. This technique has been used to deliver CRISPR-Cas9 into cells traditionally
considered challenging to transfect, such as human embryonic stem cells89, pluripotent
stem cells90, and neurons91. Electroporation is most used in in vitro settings to generate
cell and animal models by delivery of gene editing reagents. Because of the high voltage
generated with this technique, it is not suitable for in vivo delivery92. Strategies to treat
diseases with electroporation-mediated delivery of Cas9 rely on ex vivo editing of cells
and then transplanting the modified cells into patients. This strategy has been investigated
to treat sickle cell disease and β-thalassemia by delivering Cas9 into patient-derived
hematopoietic stem cells93 and has progressed into clinical trials (NCT03655678)
(NCT03745287).
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Figure 2.6 Electroporation induces transfection by application of electric currents94.
A similar strategy could be used to treat IMDs of the liver. Hepatocytes would be
isolated from an affected patient and then genetically modified ex vivo by
electroporation-mediated delivery of Cas9. The gene-corrected cells would then be
transplanted back into the patient, where they could engraft and repopulate the liver.
Studies that have investigated electroporation-mediated delivery of Cas9 into hepatocytes
are limited. In Zabulica et al., the safety and efficiency of ex vivo correction of OTC
deficiency in human hepatocytes by electroporation were investigated95. Hepatocytes
were isolated from human patients with OTCD and then electroporated with Cas9 and
donor templates with the correct OTC sequence. Editing efficiency by electroporation
was determined to be >60% in the human hepatocytes. The hepatocytes were then
transplanted into Fah and immune-deficient mice (FRGN) and managed to repopulate
80% of the liver in about 100 days following transplantation. The mice were also
reported to have improved OTC enzyme activity and normal ammonia levels95. This
study indicates that ex vivo electroporation of gene editing reagents into hepatocytes is a
valid strategy for treating IMDs of the liver. Studies investigating electroporation as a
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delivery method for Cas9 into hepatocytes are limited, so further optimization is
necessary for the clinical translation of this strategy. Challenges for electroporation
include extensive optimization required for determining the best electroporation
conditions for each cell type and the high percentage of cell death caused by the electrical
current38. Potential strategies for preventing cell death include optimizing the
electroporation buffer contents96 and modifying the electroporation vessel to prevent
variable voltage across the buffer97.
2.5.2 Lipid Nanoparticle-mediated delivery of Cas9
Lipid nanoparticles (LNPs) are structures containing a cationic head, a
hydrophobic tail, and a linker to connect these two domains98. Nanoparticles can bond to
negatively charged nucleic acids to transport them across the cellular membrane. Cationic
LNPs have recently progressed to clinical trials for CRISPR-Cas9 delivery to the liver to
treat hereditary transthyretin amyloidosis (NCT04601051). For Cas9 delivery, LNPs can
bind to Cas9 pDNA, mRNA, or the Cas9 RNP when complexed with the negatively
charged sgRNA (Figure 2.7). Each strategy has advantages and disadvantages. Cas9
pDNA and mRNA can be prepared easily in vitro and readily bind to positively charged
LNPs. The plasmid would have to undergo transcription and translation before editing
could occur. The mRNA could be translated directly into the protein once in the cell.
However, the low stability of the mRNA can lead to its degradation before translation can
occur99. Direct delivery of the Cas9 protein would allow for gene editing without needing
a translation step. This could potentially lead to reduced off-target editing and immune
response. This strategy is limited by the high molecular weight of the protein preventing
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many LNPs from being used to carry the protein across the cellular membrane100. Other
obstacles for LNP delivery include achieving high levels of transfection and limiting
delivery to target tissues101. Precise LNP engineering is necessary to guarantee targeted
transfection of liver tissue.

Figure 2.7 Lipid nanoparticles can deliver Cas9 expression as pDNA, mRNA, or
protein into cells for genome editing102.
Cationic LNPs are a promising tool for liver-targeted delivery of Cas9 to treat
IMDs of the liver. A 2016 study combined LNP and viral delivery to treat a mouse model
of HT1103. The LNPs were used to deliver CRISPR-Cas9 mRNA, while AAVs were used
to deliver sgRNA and a donor template expressing wild-type Fah. The LNPs were
formulated with C12-200, a lipid-like material that has been used to deliver siRNA into
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mice and rodent103. Gene correction was only 6% in hepatocytes after treatment;
however, this was enough to diminish symptoms such as liver damage in treated mice.
One study used zwitterionic lipids containing varying ratios of PEG to improve the Cas9
delivery rate into hepatocytes104. While they reported that decreasing the amount of PEG
increased editing rates, the editing efficiency was still low at 3.5% gene editing. In
addition, expression of Cas9 in treated mice was also found in the lungs and kidneys,
indicating the difficulties with targeting specific tissues for delivery104. Another study
delivered Cas9 mRNA and Pcsk9-targeting sgRNA into mice to lower cholesterol by
lipid-like nanoparticles formulations containing total triiodothyronine (TT3)105. Editing
efficiency with the TT3 LNPs reached as high as 39.6% in mice after four systemic
doses, with no significant liver damage reported. In Finn et al., delivery of Cas9 with
LNPs was found to achieve high levels of gene editing (>70%) in mouse liver tissue106.
Mice were injected with a single dose of Cas9 mRNA and Ttr-targeted sgRNA bound to
a biodegradable, ionizable lipid termed “LP01”. The nanoparticle was designed to
encourage hepatocyte uptake by interaction with serum proteins. After treatment, mice
had reduced levels of Ttr of up to 90% of the average level, and this reduction in Ttr
persisted for up to 12 months. Detectable levels of gene editing were observed in
harvested kidney and spleen tissue, indicating that delivery to nontargeted tissue remains
a challenge for LNPs.
2.5.3 Hydrodynamic Injection of Cas9
Hydrodynamic injection is an in vivo technique for delivering genetic material
into cells by fast injection of a large volume of liquid. This method of delivery was first
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used to introduce naked DNA into mice107. Hydrodynamic injection transfects cells by
injecting large volumes of solution containing DNA or other genetic material into the
blood. The increase in pressure from the sudden influx in volume enhances the
permeability of parenchymal and endothelial cells. In rodents, injection through the tail
vein leads to targeted delivery to liver tissue108,109. The pressure from injection creates
temporary congestion in the right ventricle, allowing the solution to flow into the hepatic
veins. The force from the flow induces transient pores in hepatocytes, and DNA cargo
can enter through these pores109. This method of delivery is particularly convenient for
liver-targeted therapies.
Hydrodynamic injection has been used to deliver CRISPR-Cas9 for gene editing
in mouse models of IMDs of the liver. In Yin et al., plasmid DNA expressing Cas9 and
the correct Fah transgene was introduced into a mouse model of HT1 by hydrodynamic
injection110. Immunohistochemical staining of liver tissue harvested from the mice
showed an average of 0.4% of cells had the corrected Fah gene. Thirty-three days after
treatment, the genetically modified cells expanded to make up nearly a third of
hepatocytes present in the liver and rescued the mice from liver damage. Similar results
were observed in Guan et al. when plasmid DNA containing Cas9 and a donor template
containing corrected F9 were delivered into the liver of a mouse model for hemophilia
B81. Initial gene editing efficiency was only 0.56%, yet edited hepatocytes managed to
expand and restore hemostasis in the treated mice. Base editors delivered by
hydrodynamic injection have been used to rescue mouse models of HT156. The mice were
injected with adenine base editors and Fah-targeting sgRNA. Gene correction was only

38

about 0.1%, but modified cells were able to expand and rescue the mice from liver
damage. In Ibraheim et al., gene editing efficiency in a Fah deficient mouse was
improved by combining AAV delivery of Cas9 with hydrodynamic injection111. Mice
were injected with AAVs containing Neisseria meningitidis Cas9 (NmeCas9) and Hpdtargeting sgRNA. Gene editing efficiency was 35% in liver tissue harvested two weeks
after treatment.
Although hydrodynamic injection has been successful in rodents, safety concerns
prevent its use in human patients. The volume of the solution injected is roughly 10% of
the mouse’s body weight. This would be equal to 5 L in a 50-kg patient to achieve the
same level of gene delivery, which is not feasible for clinical approaches109. Catheterbased approaches can achieve gene delivery with smaller volumes than traditional
injection; however, transfection rates are much lower112. Hydrodynamic injection is also
associated with cardiac dysfunction due to cardiac overflow113. These obstacles prevent
the clinical translation of hydrodynamic injection to treat IMDs of the liver.
2.6 Challenges with Therapeutic Gene Editing of the Liver
2.6.1 Off-Target Editing with CRISPR-Cas9
CRISPR-Cas9 systems for gene editing are associated with a wide range of
potential off-target activity. Off-target editing can occur at a sequence nearly identical to
the on-target site as long as a PAM sequence is adjacent. Various methods have been
developed to minimize off-target editing when using CRISPR-Cas systems. These
strategies include truncated sgRNAs, Cas9 nickases, and modified Cas9 variants.
Substituting a sgRNA with a length lower than 20 bp has been demonstrated to reduce
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off-target editing drastically at certain sites114,115. In Fu et al., it was observed that
decreasing the length of the sgRNA to 17 or 18 bp increased Cas9 specificity, sometimes
drastically by 5000-fold114. Although greatly reduced, off-target effects were not
eliminated. A follow-up study with more identified off-target sites confirmed that
truncated sgRNAs mitigate but do not eliminate off-target editing115.
Engineered Cas9 variants have been studied to determine if modifications made to
the Cas9 structure can enhance precise genome editing116. Cas9 engineering weakens the
protein’s ability to bind to non-target strands by introducing mutations that neutralize
positively charged residues that easily attach to non-target sites. One of the earliest
variants of Cas9 engineered to improve specificity is the eSpCas9116. The eSpCas9 was
generated by introducing mutations that substituted alanine in place of positive residues
in the Cas9 structure. In HEK293 cells, off-target editing was reduced with the eSpCas9
at most off-target sites, but on-target editing was also reduced. A variant protein, HiFi
Cas9-R691A (HiFi Cas9), was identified by screening an extensive array of mutant Cas9
proteins117. Introduction of the p.R691A point mutation into Cas9 has been found to
reduce off-target editing without reducing on-target editing primary human cells117,118.
While engineered variants often decrease off-target editing, they do not eliminate
unwanted editing and often reduce on-target editing117,119.
Current strategies for eliminating off-target editing have only been partially
effective. In addition, Cas9 has also been reported to cause other events that negatively
affect genomic stability. Cas9 genome editing has been observed to activate the p53
pathway and halt the cell cycle120,121. The introduction of Cas9 could lead to conditions
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where cells with inactive p53 pathways could expand. These cells would be at higher risk
for tumorigenesis because they lack a tumor suppression pathway. Large deletions in
sequences near the target site have been observed after Cas9 editing. Cas9 gene editing
has also been shown to cause DNA rearrangements and large deletions at the editing site.
Large deletions are a particular issue as they are not easily detected by PCR screening
and occur frequently following Cas9 editing122,123. Additionally, Cas9 has recently been
linked to initiating chromothripsis in cells124. Chromothripsis is a process that leads to
substantial rearrangement of sequences in one or a few chromosomes. Cells can acquire
cancer-causing mutations by chromothripsis, making its occurrence a serious concern for
therapeutic gene editing with Cas9124.
2.6.2 Cas9 Immunogenicity
A significant barrier for the clinical application of Cas9 for therapeutic gene
editing is immunity due to previous exposure. The two most used variants of CRISPRCas9 are isolated from Streptococcus pyogenes and Staphylococcus aureus. Both species
of bacteria regularly infect humans, and most people have antibody and T-cell immunity
to them. Although Cas9 is an intracellular protein, and the immune responses to these
bacteria primarily target surface proteins, studies have shown that large amounts of the
population express anti-Cas9 antibodies125,126. Immunization to Cas9 due to previous
bacterial infections could limit gene editing efficiency by removing edited cells
expressing Cas9.
The first preclinical study to identify a Cas9 specific immune response in vivo
developed an ELISA assay to identify and quantify an antibody against Cas9 in mice

41

treated with Ad vectors containing Cas9 expression82. Elevated levels of IL-2 secretion
were also observed in splenocytes exposed to Cas9. One preclinical study has indicated
that preexisting exposure to Cas9 can lead to loss of gene-edited cells127. In Li et al., mice
were injected with naked SaCas9 in the ear to determine if an immunity to Cas9 could
lead to loss of edited hepatocytes. One week later, the mice were treated with AAV8
vectors containing the Cas9 transgene and sgRNA targeting Ldlr. The researchers noted
that the mice pre-exposed to Cas9 had elevated levels of CD8+ cytotoxic T in the liver as
detected by qPCR analysis. Initially, high levels of editing were observed in the mice at
six weeks, but at twelve weeks after treatment, the percentage of edited cells had declined
drastically to 3%. Immunity because of initial exposure to Cas9 can be an issue for
treatment that would require multiple administrations of Cas9 containing reagents.
Repeated dosing of Cas9 base editors in nonhuman primates was ineffective at increasing
editing efficiency following initial treatment58.
Bypassing immunity to Cas9 remains an obstacle for therapeutic gene editing. In
patients with previous exposure, memory T cells may expand in response to Cas9
peptides on the major histocompatibility complex (MHC) class I surface. This would
pose a challenge for in vivo gene therapies as cells with Cas9 could be eliminated by
cytotoxic T cells. Editing cells ex vivo with transient forms of Cas9 may evade the
immune system as cells could be cultured until they no longer express Cas9 peptides.
However, there are currently no studies with an estimated period of culturing required to
remove the expression of Cas9 on the MHC surface.
2.6.3 Conclusions
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While several groups have mode progress for treating IMDs of the liver by
therapeutic gene editing, there remains a lack of safe and effective method for delivering
Cas9 into hepatocytes. Current gaps in the literature include how primary hepatocytes
respond to electroporation-mediated delivery of CRISPR-Cas9, if chemically modified
sgRNA enhance gene editing in liver cells, and using chalcogen-containing, bioreducible
LNPs for mRNA delivery into hepatocytes. This study will investigate nonviral methods
for ex vivo delivery of CRISPR-Cas9 components into hepatocytes for therapeutic gene
editing. We will assess transfection efficiency of electroporation- and LNP-mediated
delivery of Cas9. We will also examine potential toxicity for hepatocytes by MTT and
albumin assays to determine optimal conditions for nonviral delivery of Cas9 into
primary hepatocytes.
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CHAPTER THREE
SPECIFIC AIM 1: OPTIMIZE ELECTROPORATION-MEDIATED DELIVERY
OF HPD-TARGETING CRISPR-CAS9 INTO LIVER-DERIVED CELLS AND
PRIMARY HEPATOCYTES
3.1 INTRODUCTION
Therapeutic gene editing has recently advanced to clinical trials for inherited
metabolic diseases (IMDs) of the liver1. Despite the unprecedented capacity to induce
double-stranded breaks at nearly any site in the genome, a significant barrier for liverdirected gene-editing therapies using CRISPR-Cas9 nucleases is the absence of safe and
effective protocols for delivering CRISPR components into primary hepatocytes. Adenoassociated viral vectors (AAVs) are the most commonly used delivery method for
CRISPR-Cas9 due to the availability of well-established protocols and high transduction
efficiency: Many preclinical studies have reported successful CRISPR-Cas9-mediated
gene editing using AAVs in animal models of human IMDs of the liver, including
phenylketonuria2, ornithine transcarbamylase deficiency3, and familial
hypercholesterolemia4.
Diverse AAV serotypes show strong liver tropism and promising outcomes in
clinical trials5,6, making AAVs a practical candidate for liver-directed gene editing.
However, AAVs have immunogenicity risks stemming from preexisting immunity due to
prior exposure to the wild-type virus, which results in the loss of transduced hepatocytes
and therapeutic failure6–13. Further, AAVs have the potential to integrate into on- and offtarget Cas9 sites14,15. Insertional mutagenesis of AAV vectors caused hepatocellular
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carcinoma in neonatal mice16,17. Because DNA cargo delivered by AAVs persist as stable
episomes, there are concerns that persistent Cas9 expression may occur, resulting in
increased off-target activity and genotoxicity18. In addition, Cas9 immunity is highly
prevalent, with up to 78% of humans having anti-Cas9 IgG antibodies and Cas9-specific
T cells19,20. Anti-Cas9 cytotoxic T cells are particularly problematic: They can eliminate
any cell presenting Cas9 peptides on their major histocompatibility complex class I
surface molecules. In the study by Li et al., AAV delivery of CRISPR-Cas9 in mice
immunized against Cas9 led to cytotoxic T cell responses and the elimination of geneedited hepatocytes21. Self-deleting AAVs were proposed to overcome Cas9 immunity22
but cannot entirely remove Cas9 and would require short-term immunosuppression
therapy to avoid an immune response against the AAV capsid. Thus, immunogenicity
complications pose a significant obstacle to the clinical translation of AAV for gene
editing.
Nonviral methods have the potential to address challenges associated with AAVmediated delivery of gene-editing reagents into target cells1. Nonviral approaches allow
for the possible delivery of transient, potent forms of Cas9, such as mRNA and
ribonucleoproteins (RNPs), which exist for shorter periods than plasmid DNA and are
associated with higher gene editing specificity23–25. Electroporation is a nonviral
approach that involves utilizing high-voltage currents to permeabilize membranes to
deliver biomolecules into cells. Current CRISPR-Cas9 clinical trials use electroporation
for gene editing T-cells and CD34+ hematopoietic stem and progenitor cells (HSPCs)26–
28

. The advantage of electroporation is its potential to be used in a wide array of cell types
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at all cell cycle stages1,29. Electroporation is particularly powerful for CRISPR-Cas9
mediated gene editing in target cells: It is amenable to delivery of synthetic chemically
modified sgRNA along with Cas9 mRNA or proteins to improve on-target gene editing
and reduce off-target activity25,30. In contrast to in vivo gene editing approaches, ex vivo
gene editing using electroporation is safer because the gene editing is limited to the
intended target cell type and not the whole organism. However, ex vivo gene editing is
associated with more processing steps: cell isolation from the host, gene editing, and
transplantation.
In recent preclinical studies, ex vivo gene editing in hepatocytes followed by
transplantation corrected a mouse model of hereditary tyrosinemia type I (HTI). HTI is
characterized by homozygous loss-of-function mutations in the gene encoding
fumarylacetoacetate hydrolase (Fah). Fah-/- mice were rescued by transplanting genecorrected hepatocytes co-transduced ex vivo using lentiviral vectors containing Fahaiming CRISPR-Cas9 and AAV vector containing a donor template31. In a separate study,
hepatocytes transduced utilizing a pair of AAVs to deliver Fah-CRISPR-Cas9 and donor
template followed by culturing for up to 72 hours were capable of engraftment in vivo
and prevented liver failure32. These studies demonstrate the feasibility of ex vivo gene
editing in hepatocytes to treat IMDs of the liver.
The shortage of disease models represents an additional major challenge for
developing novel therapies for IMDs of the liver. Isolated primary human hepatocytes are
the gold standard for drug development studies for treating liver disease, but diseasespecific hepatocytes are limited. Induced pluripotent stem cells (iSPCs) differentiated
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into hepatocyte-like cells are an alternative to primary hepatocytes for disease modeling
and drug discovery studies33. The advantage of iPSC-derived hepatocyte-like cells is that
the precursor cells can be edited using CRISPR-Cas9 and screened to identify diseasespecific mutations for high throughput drug screens. The disadvantage of iPSChepatocytes-likes cells is that they provide insufficient levels of engraftment to make
disease models34. An alternative disease model development strategy for IMDs of the
liver involves ex vivo gene editing in primary human hepatocytes followed by
transplantation into FRGN mice (Fah−/−/Rag2−/−/Il2rg−/− on the NOD-strain background)
that supports the replacement of the native liver by human hepatocytes35. Electroporation
is an attractive delivery method for generating disease models because it allows for rapid
ex vivo delivery of DNA, RNA, and proteins into primary hepatocytes. The
electroporated gene-edited cells can subsequently be transplanted into FRGN mice to
generate novel models of liver disease.
In this study, we demonstrate the use of electroporation to deliver CRISPR-Cas9
into human and mouse hepatocytes and evaluate Cas9 on-target activity and viability. To
show proof of principle gene editing for an IMD of the liver, we designed CRISPR-Cas9
targeting hydroxyphenylpyruvate dioxygenase (Hpd), a therapeutic target for HTI36. Our
study results are the first to demonstrate electroporation-mediated delivery of CRISPRCas9 into primary hepatocytes and show high levels of gene editing.
3.2 MATERIALS AND METHODS
Hepatocyte isolation
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Animal care and experiments were all under the guidelines and approved
protocols of the Institutional Animal Care and Use Committee at Clemson University.
Hepatocytes were isolated from anesthetized male C57BL/6J mice aged 8-10 weeks old
using a three-step perfusion procedure as described in37. Briefly, the inferior vena cava
was cannulated and perfused with three solutions. The final solution to complete in situ
digestion consisted of EBSS with Ca2+/Mg2+ supplemented with 10 mM HEPES pH 7.4
and 0.094 Wunsch units/mL Liberase (Sigma Aldrich). The liver was dissected carefully
without injuring the capsule and disrupted using scissors. The dissociated cells were then
collected and added to ice-cold high glucose Dulbecco’s Modified Eagle’s Medium
(DMEM, Gibco) supplemented with 10% FBS. The cells were pelleted by centrifugation
and washed several times. Electroporation was conducted using isolated hepatocytes with
a yield of 10-40 x 106 cells and 80% cell viability (measured by trypan blue staining).
CRISPR sgRNA design and DNA constructs
The sgRNAs for transfection in mouse and human cells were designed using the
Benchling CRISPR Guide RNA Design Tool (benchling.com/crispr). Sequences for
different sgRNAs targeting mouse Hpd and human HPD are shown in Table 3.1. The
sgRNAs transfected into 3T3 cells, Hepa 1-6 cells, and primary mouse and human
hepatocytes were obtained from TriLink Biotechnologies or Horizon Discovery
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Biosciences. The sgRNAs transfected into HEK293 cells were obtained from Integrated
DNA Technologies.
Table 3.1 sgRNA sequences for Cas9 comparisons in cultured and primary cells. (A)
Guide sequences targeting exon 3 of Hpd. Sequences bolded were used for
transfections shown in figures 1-3. (B) Guide sequences for targeting exon 5 of HPD.
Bolded sequence was used for transfections shown in Figures 3.1 and 3.5. sgRNA
sequences include the PAM-site.
(A)
sgRNA
Hpd-1
Hpd-2
Hpd-3
Hpd-4

Sequence
CTTGGCATTGCCAACCCAGAAGG
CCGGTTCCTCCATTTCCACTCGG
CAACCCAGAAGGTCACCGAGTGG
AGGTCACCGAGTGGAAATGGAGG

(B)
sgRNA
HPD-1
HPD-2
HPD-3
HPD-4

Sequence
TCAGCCATGTAATCAAACAAGGG
TTTGAACCTCTAGCCTACAGGGG
TCCAGGCCCCTGTAGGCTAGAGG
ACCGGTCTCCAGGCCCCTGTAGG

The pX330-U6-Chimeric_BB-CBh-hSpCas9 plasmid, a gift from F. Zhang
(Addgene plasmid #42230), was transformed into DH5α competent cells (Invitrogen).
Plasmid DNA was extracted using the Qiagen midi prep protocol. Using standard cloning
procedures, annealed oligonucleotides containing guide sequences targeting the mouse
Hpd locus (Eurofins Genomics) were ligated into the pX330-U6-Chimeric_BB-CBhhSpCas9 plasmid. Plasmids encoding Hpd-aiming CRISPR-Cas9 were evaluated in NIH
3T3 cells.
For constructing the pX330-U6-Chimeric_BB-CBh-hSpCas9Δ179-595 plasmid
(hereafter Cas9 plasmid DNA), 416 bp gRNA scaffold located between the NdeI sites at

63

179 and 595 was removed by restriction enzyme NdeI treatment of the pX330-U6Chimeric_BB-CBh-hSpCas9 plasmid. Briefly, 2.5 µg of the plasmid DNA was digested
with 25 units of NdeI (New England BioLabs) at 37oC for 30 minutes in CutSmart
Buffer. The enzyme was inactivated by heating for 20 minutes at 60oC. The resulting
8090 bp and 416 bp fragments were separated on 1.5 % agarose gel containing Ethidium
Bromide. The DNA was visualized under UV light, and the larger 8090 bp fragment was
excised for purification with QIAquick Gel Extraction Kit (Qiagen). Next, 25 ng of the
purified linear fragment was ligated with T4 DNA ligase enzyme (New England
BioLabs) for 4 hours at room temperature, then transformed into DH5α cells. The Cas9
plasmid DNA was isolated using the QIAprep Spin Miniprep kit (Qiagen), and the
deletion of the 416 bp fragment was verified using agarose gel electrophoresis.
Cell culture and electroporation
Mouse NIH 3T3 (Sigma Aldrich), Hepa 1-6 cells (ATCC), and primary
hepatocytes were cultured at 37°C in a humidified incubator with 5% CO2 and ambient
oxygen levels. Cells were maintained in DMEM (Gibco) supplemented with 10% FBS, 4
mM L-glutamine, and 1X antibiotic-antimycotic. Cryopreserved C57BL/6J plateable
mouse hepatocytes (Product code: MBCP01, Lonza) isolated from 4-month-old male
mice were thawed using Rodent and Monkey Cryopreserved Hepatocyte Thawing
Medium (Lonza) according to the manufacturer’s instructions. Cryopreserved and freshly
isolated mouse hepatocytes were maintained in Hepatocyte Plating Medium (Lonza) in 6well Corning Primaria plates. Following cell attachment, the media was replaced with
Hepatocyte Maintenance Medium (Lonza). At 24 hours after electroporation, 0.25
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mg/mL Corning Matrigel basement membrane matrix was added as an overlay.
Cryopreserved human hepatocytes were obtained from Lonza. Demographic information
on the human hepatocyte donors is found in Table 3.2. According to the manufacturer’s
instructions, human hepatocytes were thawed using Human Cryopreserved Hepatocyte
Thawing Media (Lonza). Hepatocytes were maintained for three days in HCM
Hepatocyte Culture Medium Bullet Kit (Lonza). Twenty-four hours after plating, 0.25
mg/mL Corning Matrigel basement membrane matrix was added as an overlay.

Table 3.2 Demographic information of cryopreserved human hepatocyte donors for
electroporation experiments.
Catalog
Number
HUCPG
HUCPG
HUCPI

Lot Number
HUM191441
HUM183001
HUM182411

Donor Age
19 years
20 years
5 years

Donor
Race
Caucasian
Caucasian
Hispanic

Donor Sex
Female
Female
Male

The NIH 3T3, Hepa 1-6, HEK293 cells, and human hepatocytes were
electroporated with a 4D-Nucleofector X Unit (Lonza). NIH 3T3 cells were
electroporated using program EN-158, SG Cell Line 4D-Nucleofector solution (Lonza),
and conditions: 20 µL SG nucleofection buffer, 2.2 x 105 cells, 0.5 µL of 20 µg/µL
sgRNA (TriLink Biotechnologies), and 1.7 µL of 61 µM 3NLS SpCas9 (Product code:
1074182, Integrated DNA Technologies). For reactions with Cas9 RNPs, the SpCas9
RNP was incubated with the Hpd targeting sgRNA for 20 minutes at room temperature.
Hepa 1-6 and HEK293 cells were electroporated using the SF Cell Line 4D-Nucleofector

65

solution (Lonza) and the 4D-Nucleofector programs CM-138 and CM-130, respectively.
The Hepa1-6 and HEK293 cell electroporation conditions were as follows: 20 µL SF
nucleofection buffer; 1.2 x 105 cells; 0.5 µL of 20 µg/µL sgRNA; and 0.76 µL of 1.32
µg/µL Cas9 pDNA, 1 µL of 1 µg/µL CleanCap Cas9 mRNA (Product code: L-72061000, TriLink Biotechnologies), 1.7 µL of 61 µM 3NLS SpCas9, or 1.7 uL of 61µM
3NLS HiFi SpCas9 (Product code: 1078728, Integrated DNA technologies). For cell
lines, delivery efficiency was determined by separately electroporating cells with 0.4 µL
of 1 µg/µL pmaxGFP (Lonza) and analyzing cells using a Guava Flow Cytometer 24
hours after electroporation. Primary human hepatocytes were electroporated using
modified procedures described in38. Briefly, hepatocytes were electroporated with P3
Primary Cell 4D-Nucleofector solution (Lonza), program CA-137, and electroporation
conditions: 100 µL P3 nucleofection buffer, 1.8 µL of 20 µg/µL sgRNA, 5 µL of 61 µM
V3 SpCas9 (Product code: 1081059, Integrated DNA Technologies) or 5 µL of 61 µM
V3 HiFi SpCas9 (Product code: 1081061, Integrated DNA Technologies), and 3 µL of
100 µM Electroporation Enhancer (Product code: 1075916, Integrated DNA
Technologies). Primary mouse hepatocytes were electroporated using Lonza
Nucleofector 2b (program T-028), Mouse/Rat Hepatocyte Nucleofector solution (Lonza),
and electroporation conditions: 100 µL Mouse/Rat Hepatocyte Nucleofector solution; 1.2
x 106 cells; 1.5 µL of 20 µg/µL sgRNA; and 4 µL of 1 µg/µL CleanCap Cas9 mRNA, 4.9
µL of 61 µM 3NLS SpCas9, 4.9 µL of 61 µM 3NLS HiFi SpCas9. The delivery
efficiency in primary mouse hepatocytes was estimated by electroporating cells with
CleanCap eGFP mRNA and analyzing the percentage of GFP-positive cells using phase
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and fluorescence microscopy images 24 hours after electroporation. Hepatocytes were
stained with trypan blue and counted for cell viability using a hemocytometer.
Viability and albumin assays
Primary human and mouse hepatocyte viability was measured immediately after
electroporation by cell counting after trypan blue staining using a hemocytometer. In
addition, MTT assays (Sigma Aldrich) were performed on the mouse and human primary
hepatocytes 24 hours after electroporation, according to the manufacturer’s instructions.
Briefly, the medium was replaced with fresh culture medium supplemented with 12 mM
MTT stock solution (prepared by adding 1 ml of PBS to 5 mg of MTT), and the cells
were incubated overnight. The produced formazan was dissolved in SDS-HCl solution,
incubated for 4 hours at 37°C, and the absorbance was measured at 570 nm using a
Biotek microplate reader.
For albumin quantification, enzyme immunoassays were carried out for mouse
and human albumin using the cell culture mediums collected after 1-day postelectroporation with the AssayMax mouse/human albumin ELISA kits per the
manufacturer’s instructions (Assaypro, St. Charles, MO). Briefly, 50 μl of standard or
sample were added per well and incubated. After washing, 50 μl of biotinylated antibody
was added per well and incubated. After washing, 50 μl of SP conjugate was added per
well. After incubation, 50 μl of chromogen substrate was added per well and incubated.
Lastly, 50 μl of stop solution was added per well, and the absorbances were read
immediately at 450 nm.
Identification and ranking of off-target sites
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Potential off-target sites for each HPD-targeting sgRNA design were identified
using CRISPR-Off-target Sites with Mismatches, Insertions, and Deletions (COSMID)39.
The CRISPR guide sequence was entered into the program, and a list of related
sequences with up to three or fewer base mismatches or sites containing a single base
insertion or deletion were considered for potential off-target sites. COSMID generated a
list of these sites adjacent to an NRG or NGG PAM site. Sites were then ranked by
lowest score and priority given to NGG mismatches over NRG mismatches.
Measuring allele alterations using TIDE
Genomic DNA from electroporated cells was extracted using QuickExtract DNA
Extraction Solution (Lucigen) according to the manufacturer’s instructions. Primers used
for PCR amplification of target sites are listed in Table 3.3. PCR was performed with
AccuPrime Taq DNA Polymerase (Invitrogen) following the manufacturer’s instructions
for 35 cycles (94°C for 30 seconds; 57°C for 30 seconds; 68°C for 1 minute). Amplicons
were purified by QIAquick PCR Purification kit (Qiagen) or Agencourt AMPure XP
beads (Beckman Coulter) and then subjected to Sanger sequencing (Eurofins Genomics).
Sanger sequence reads were uploaded to Tracking of Indels by Decomposition (TIDE)40
and compared to a control sequence to quantify Cas9 generated indels at the target site.
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Table 3.3 PCR primers for amplification of Hpd and HPD for on-target TIDE
analysis.
Mouse
FWD
REV

GGTCACCCATACTGTTCTCACG
AGTCCTAGCCTGGCCTGGAT

Human
FWD
REV

TGTGCAGGCAGCAGTCTATC
GAAACTAGGAAGGGCCGTGT

Statistical Analysis
The data generated in each experiment were imported into Prism 8.0 (GraphPad
Software). One-way ANOVA and Tukey’s multiple comparisons tests were performed to
determine the statistical significance of means for comparing on-target indels for Hepa 16 experiments and the viability and functionality assays. Unpaired t-tests were performed
to compare on-target indels between the different samples. P-values < 0.05 were
considered significant.
3.3 RESULTS
First, we optimized electroporation-mediated delivery of CRISPR-Cas9 targeting
mouse Hpd to demonstrate proof-of-principle gene editing for an IMD of the liver. We
designed four CRISPR guide sequences targeting exon 3 in the Hpd locus (Figure 3.1A)
using Benchling (https://benchling.com). The Streptococcus pyogenes Cas9 (hereafter
Cas9) was used for all experiments described in the study. Plasmid DNA encoding the
sgRNA and Cas9 were electroporated into NIH 3T3 cells, and indels were detected via
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Sanger sequencing and analyzed using TIDE. The sgRNA design labeled Hpd-3 provided
the highest on-target indels (Figure 3.1B) and was used in subsequent experiments.
We next evaluated how different forms of Cas9 delivered using electroporation
affected the gene-editing efficiency in Hepa 1-6 cells (Figure 3.2). We compared three
Cas9 cargos: Cas9 plasmid DNA (pDNA), mRNA, and RNP. The Cas9 plasmid DNA is

Figure 3.1 Comparison of Cas9 sgRNA designs targeting Hpd in NIH 3T3 cells.
(A) Schematic diagram of guide sequences targeting exon 3 of Hpd. PAM sites are
underlined. (B) On-target indels in NIH 3T3 cells electroporated with plasmid DNA
containing the sgRNA and Cas9 for the different guide sequence designs targeting
Hpd.
the pX330-U6-Chimeric_BB-CBh-hSpCas9Δ179-595 that had been modified to remove the
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guide RNA scaffold sequence. The plasmid DNA and mRNA encoding for Cas9 were codelivered with Hpd-aiming sgRNA. Cas9 protein was complexed with Hpd-sgRNA
before electroporation into cells for the RNP delivery. The transfection efficiency in
Hepa 1-6 cells was >85%, as estimated by electroporating pmaxGFP plasmid DNA
(Table 3.4). In contrast to Cas9 plasmid DNA providing on-target indels of 48.6%, Cas9
mRNA and WT Cas9 RNPs provided higher on-target indels (mean 89.3% and 80.0%,
respectively, p <0.9799). We also tested the HiFi Cas9-R691A variant (HiFi Cas9) that
reduces off-target activity while maintaining robust on-target gene editing in CD34+
HSPCs41–43. Consistent with these previous studies, the on-target indels generated by the
HiFi Cas9 RNPs were comparable to Cas9 mRNA and WT Cas9 RNP (Figure 3.2) in
Hepa 1-6 cells.

Table 3.4 Electroporation efficiency in Hepa 1-6 cells. H1-H3 refer to Cas9
comparison transfections performed in Hepa 1-6 cells (Figure 3.1). Electroporation
efficiency was quantified by electroporation of Hepa 1-6 cells with pmaxGFP vector
(Lonza) and measuring fluorescence by Millipore Guava easyCyte HT Flow
Cytometer at 24-hours post electroporation.
Experiment
H1
H2
H3

Electroporation Efficiency
85.9%
96.3%
91.6%

We evaluated the Hpd-targeting CRISPR-Cas9 electroporated as Cas9 mRNA and
RNPs in cryopreserved primary mouse hepatocytes. The electroporation efficiency was
measured in mouse hepatocytes using fluorescence microscopy 24 hours after
electroporating eGFP mRNA (Figure 3.3A). The mean GFP expression in mouse
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hepatocytes was 67%, and the cell viability was 31% after electroporation using program
T-028 (Table 3.5). When we applied our electroporation protocol to introduce

Figure 3.2 On-target Cas9 activity in electroporated Hepa 1-6 cells. Dots
represent different electroporation experiments, and horizontal bars represent the
means (n = 3). Statistical significance is indicated by asterisks, * is for p < 0.05 and
** is for p < 0.01. Mock samples were electroporated with pmax-GFP.
Hpd-CRISPR-Cas9, we observed high levels of on-target indels of >60% for Cas9
mRNA and RNP (Figure 3.3B) in primary mouse hepatocytes. Consistent with results in
Hepa 1-6 cells, we observed comparable on-target indels for the WT and HiFi Cas9
RNPs (Figure 3.3B) in cryopreserved mouse hepatocytes (mean 73.3% and 64.5%,
respectively, p = 0.9654).
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Figure 3.3 On-target Cas9 activity in electroporated cryopreserved primary
mouse hepatocytes. (A) Phase-contrast and fluorescence microscopy image of mouse
hepatocytes electroporated with eGFP mRNA. The scale bar corresponds to 400 𝜇m
(B) Comparison of on-target indels for primary hepatocytes electroporated with Cas9
mRNA, WT RNP, and HiFi RNP. Mock samples were electroporated with eGFP
mRNA. Dots represent different electroporation experiments, and horizontal bars
represent the means (n = 3).
We next evaluated Hpd-CRISPR-Cas9 in mouse hepatocytes freshly isolated from
C57BL/6J mice, electroporated within 2 hours after collagenase digestion of the liver,
and subsequently plated. To determine the effects of electroporation on the hepatocyte
viability and functionality, we performed MTT and albumin assays on hepatocytes after
electroporation (Figure 3.4A). Further, we measured the cell transfection efficiency using
microscopy at 24 hours after electroporating eGFP mRNA (Figure 3.4B).
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Table 3.5 Electroporation efficiency and viability in cryopreserved mouse
hepatocytes following electroporation. P1-P3 refer to electroporation experiments
performed in mouse hepatocytes following thawing (Figure 3.3). Electroporation
efficiency was quantified by counting the percentage of GFP positive cells using
microscopy.
Experiment
P1
P2
P3

Electroporation Efficiency
72.7%
63.6%
63.4%

Viability
21.1%
53.1%
18.8%

We observed higher levels of on-target gene editing using the Cas9 RNP than mRNA
(mean 78.4% and 47.4%, respectively, p = 0.0331) in freshly isolated hepatocytes (Figure
3.4C). There was no difference in the MTT and albumin assay results for hepatocytes
electroporated with Cas9 mRNA, WT RNP, or GFP mRNA (Figure 3.4D and 3.4E),
which indicates that the CRISPR gene editing process does not adversely affect the
hepatocyte viability or functionality.
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Figure 3.4 Analysis of on-target Cas9 activity and viability in freshly isolated
mouse hepatocytes after electroporation. (A) Timeline of experimental procedures.
MTT assay and gDNA extraction were performed in separate wells. (B) Phasecontrast and fluorescence microscopy image of hepatocytes electroporated with eGFP
mRNA. The scale bar corresponds to 400 𝜇m (C) Comparison of on-target indels for
isolated mouse hepatocytes treated with Cas9 mRNA or WT Cas9 RNP. (D) Viability
normalized to untransfected control following electroporation as determined by MTT
assay. (E) Albumin levels in conditioned media normalized to untransfected control.
Dots represent different electroporation experiments, and horizontal bars represent the
means (n = 3). Asterisks indicate statistical significance, * is for p < 0.05.
Next, we evaluated the impacts of electroporation to introduce CRISPR-Cas9 into
primary human hepatocytes. We tested four different sgRNA designs targeting HPD in
HEK293 cells (Figure 3.5). The four sgRNA designs were electroporated into HEK293
cells alongside Cas9 RNPs using a Lonza 4D nucleofector device, and the on-target
indels were quantified using TIDE (Figure 3.5B). Potential off-target sites for HPD were
determined using COSMID. After comparing the on-target indels and the number of
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potential off-targets, we selected sgRNA we labeled HPD3 as it had high levels of ontarget editing but the fewest potential off-target sites predicted in COSMID (Table 3.6).

Table 3.6 Number of potential off-target sites for HPD-targeting sgRNAs. Offtarget sites for the HPD-targeting sgRNAs shown in Supplementary Fig. 4B were
identified using COSMID. Conditions for identifying off-target sites included sites
with up to three mismatches, a 1-bp insertion, a 1-bp deletion in the sequence, and up
to two mismatches in the PAM sequence. Duplicate sites were filtered from COSMID
output.
Sequence
Name

sgRNA Sequence

Query Sequence

HPD1

TCAGCCATGTAATCAAACAA NCAGCCATGTAATCAAACAA
NRG

HPD2

TTTGAACCTCTAGCCTACAG

HPD3

TCCAGGCCCCTGTAGGCTAG

HPD4

ACCGGTCTCCAGGCCCCTGT

NTTGAACCTCTAGCCTACAG
NRG
NCCAGGCCCCTGTAGGCTAG
NRG
NCCGGTCTCCAGGCCCCTGT
NRG

Total #
of OffTarget
Sites
474
333
129
170

We electroporated human hepatocytes with WT and HiFi Cas9 RNPs. When
plated, electroporated human hepatocytes appeared to have identical cell morphology as
the untreated hepatocytes (Figure 3.6A). We observed similar levels of on-target editing
for the WT RNP and HiFi RNP (mean 52.4% and 36.7%, respectively, p = 0.5558) in
cryopreserved primary human hepatocytes taken from three different donors (Figure
3.6B). The MTT and albumin assays showed high average viability (>60%) for all
electroporated cells (Figure 3.6C and 3.6D), such that there was no significant difference
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between any groups. These results indicate that the process of CRISPR-Cas9 editing
likely does not adversely affect primary human hepatocyte viability.

Figure 3.5 Comparison of Cas9 sgRNA designs targeting HPD in HEK293 cells.
(A) Schematic diagram of guide sequences targeting exon 5 of HPD. PAM sites are
underlined. (B) On-target indels in HEK293 cells electroporated with the different
CRISPR-Cas9 designs target HPD delivered as RNPs.
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Figure 3.6 On-target Cas9 activity and viability in electroporated human
hepatocytes. (A) The first image shows untransfected primary human hepatocytes 24
hours after plating. The second image shows plated primary human hepatocytes 24
hours after electroporation. (B) On-target indels for human hepatocytes electroporated
with WT RNP and HiFi RNP. (C) Viability normalized to untransfected control as
determined by MTT assay. (D) Albumin levels in conditioned media normalized to
untransfected control cells. Dots represent different electroporation experiments, and
horizontal bars represent the means (n = 3). Mock samples were hepatocytes
electroporated with eGFP mRNA.
3.4 DISCUSSION
The present study was performed to (1) determine whether electroporation
efficiently delivers CRISPR-Cas9 into primary hepatocytes without adverse effects and
(2) optimize the form of CRISPR components electroporated into hepatocytes. Here, we
show that electroporation of CRISPR-Cas9 results in high gene editing efficiencies in
primary mouse and human hepatocytes when delivered as an RNP with overall low levels
of off-target alterations. Consistent with previous studies23,25, when we electroporated
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Hpd-CRISPR-Cas9 into the Hepa1-6 hepatocellular carcinoma cell line, we observed
higher on-target efficiency for Cas9 RNPs and mRNA compared to Cas9 plasmid DNA.
The HiFi Cas9-R691A variant did not see a decrease in on-target gene editing, as shown
in other studies.
The study results show that electroporation of CRISPR-Cas9 RNPs in primary
mouse and human hepatocytes results in robust gene editing. We also observed similar
levels of cell viability (>60%) and albumin production for WT and HiFi Cas9 RNPs in
electroporated human primary hepatocytes. We anticipate that the electroporation
procedure in primary hepatocytes will have utility for therapeutic gene-editing and the
development of liver disease models.
Nonviral delivery of CRISPR-Cas9 can address the shortcomings of AAVs while
advancing therapeutic applications of liver-directed gene editing. Lipid nanoparticles
(LNPs) is the only nonviral delivery approach that has progressed to clinical trials for
liver-directed gene-editing therapy (NCT04601051). Like electroporation, LNPs are
suitable for delivering CRISPR-Cas9 as amRNA44,45 and RNPs46. In preclinical studies,
LNP-mediated delivery of Cas9 mRNA and chemically modified sgRNA targeting Ttr in
mice resulted in high levels of gene editing (>70%) and >97% knockdown in serum
protein levels to correct transthyretin amyloidosis disease indication47. However, toxicity
from nanoparticles is a concern that will be evaluated in clinical trials for therapeutic
gene editing in patients with hereditary transthyretin amyloidosis. Another problem with
LNPs is that they will likely deliver gene-editing reagents to tissues beyond the targeted
tissue. In contrast, nonviral delivery performed ex vivo is potentially safer than systemic
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delivery because the gene editing is in only the intended target cell type and not the
whole organism. An additional advantage of the ex vivo approach is the opportunity to 1)
maintain target cells in culture until Cas9-derived peptides are no longer expressed on the
MHC I surface proteins that can trigger cytotoxic T cells, 2) screen for off-target gene
editing, and 3) expand gene-edited hepatocytes using artificial or living bioreactors
before transplantation.
The electroporation approach we used in the present study has attractive attributes
for CRISPR-mediated therapeutic gene knockdown applications. The studies of
Pankowicz et al. described the use of in vivo hydrodynamically delivered dual CRISPRCas9 plasmid DNA encoding a pair of gRNAs to induce the deletion of exons 3 and 4 in
Hpd to treat HTI in mice36. The dual CRISPR-Cas9 approach for making deletions within
the same locus is associated with a higher probability of unwanted off-target effects and
genotoxic events than using a single gRNA48. Further, our electroporation procedure can
be used in autologous hepatocytes from the patient’s resected liver followed by
transplantation back into the patient to repopulate the liver and is more clinical feasibility
compared to hydrodynamic transfection used in36 for treatment of HTI mice.
Electroporation has been applied for ex vivo delivery of CRISPR-Cas9 into CD34+
HSPCs24,26,49,50 and T-cells27,51 to treat genetic and acquired diseases in clinical trials.
However, the weakness of ex vivo gene editing for liver-directed therapy is that only a
limited number of disease indications have a natural selective advantage for gene-edited
hepatocytes compared to native hepatocytes. Recently, disruption of Cypor using a single
CRISPR-Cas9 gRNA was shown to enable the enrichment of gene-edited hepatocytes to
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50% of the liver mass using Tylenol52, representing a promising approach selected for a
small population of gene-edited hepatocytes for potentially any IMD of the liver. Another
potential therapeutic application of our electroporation approach is for allogenic
hepatocyte cell transplantation therapy whereby hepatocytes from healthy donors are
engineered using CRISPR-Cas9 to inactivate genes that would avoid graft-vs-hostdisease against donor hepatocytes analogous to “off-the-shelf” CAR T cells.
Electroporation is attractive for engineering allogeneic “off-the-shelf” hepatocytes
because it enables rapid delivery into suspension cells that avoids excessive culturing that
can cause loss of cell functionality.
One significant barrier to developing novel therapies for IMDs of the liver is the
absence of animal models of human diseases that can be used to conduct studies
translated to the clinic. The FRGN chimeric model supports liver humanization and
enables repopulation of up to 95% of the liver by human donor hepatocytes35,53. The
recent study by Zabulica et al. demonstrated the transplantation of patient-derived donor
human hepatocytes into FRGN mice to generate a humanized model of ornithine
transcarbamylase deficiency (OTCD)38. The weakness of this approach is that the
chimeric humanized-liver FRGN mice are immune-compromised, which limits the type
of experiments that can be conducted. Alternatively, mouse hepatocytes edited using
CRISPR-Cas9 ex vivo can be transplanted into the Fah-/- mice31,32 to repopulate the liver
with edited hepatocytes to generate mouse models of human disease containing a
functional immune system. A significant development in this report is the establishment
of electroporation procedures for editing primary mouse hepatocytes. We anticipate that
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hepatocytes edited using our electroporation method can be transplanted into Fah-/- mice
to repopulate the liver.
3.5 CONCLUSION
In summary, this study demonstrates that electroporation results in high delivery
efficiencies in primary mouse and human hepatocytes ex vivo as an effective and rapid
approach for liver-directed gene editing. We anticipate that our results will stimulate
further studies on electroporation and other nonviral methods for ex vivo liver-directed
gene therapies and the generation of disease models.
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CHAPTER FOUR
SPECIFIC AIM 2.1: EVALUATE IF CHEMICAL MODIFICATIONS TO THE
SGRNA IMPROVE CAS9 EFFICACY IN PRIMARY HEPATOCYTES
4.1 INTRODUCTION
CRISPR-Cas9 genome editing relies on gRNA, a small RNA targeting sequence,
to identify the sequence of DNA to be edited. The gRNA comprises a 20 nucleotide
CRISPR RNA (crRNA) sequence and a trans-activating crRNA (tracrRNA). The
tracrRNA acts as a binding scaffold for the nuclease, while the 20-nucleotide crRNA is
complementary to the target site. The two components can be combined into a single
guide RNA strand (sgRNA). The sgRNA forms a gRNA:DNA heteroduplex with the
target site through Watson and Crick base pairing1. Formation of the heteroduplex is
necessary for Cas9 to introduce a DSB into the DNA. Inside the cellular environment,
RNA reagents are highly unstable and susceptible to degradation by endo/exonucleases2–
4

. Studies have shown that codelivery of unmodified gRNA with Cas9 pDNA and mRNA

into mammalian cells leads to a drastic reduction in gene editing efficiency5,6 possibly
due to degradation of the sgRNA before translation of the Cas9 protein. Preventing
degradation of the sgRNA before it can complex with the Cas9 protein remains an
obstacle to successful Cas9 gene editing. Another concern when using Cas9 RNPs is that
sgRNAs are typically transcribed from phage polymerases and contain a 5’-triphosphate
group7. The 5’-triphosphate group can activate type I interferon-mediated immune
responses leading to cell death and loss of gene editing7,8.
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Chemical modifications can improve RNA stability and prevent degradation by
nucleases2,9–13. Studies have found that nuclease resistance in siRNA is improved by
substituting an O-methyl group for the hydroxyl at the 2’ position of the ribose12,13. The
2’-O-methyl RNA naturally occurs in mammalian ribosomal RNAs, transcriptional
RNAs, microRNAs, small nuclear RNAs, and in some mRNAs14. The 2’-OH is highly
susceptible to hydrolysis and is necessary for nuclease cleavage13. Replacing it with a
methyl group improves the stability of RNA13,15. Adding a phosphorothioate (PS) linkage
to the RNA structure has also been shown to reduce nuclease degradation16. In the first
study to deliver Cas9 with a 2’-O-methyl modified sgRNA, the addition of the methyl
group was found to modestly improve gene editing in human primary T cells and
CD34+ hematopoietic stem and progenitor cells6. In addition, the delivery of Cas9 with
sgRNAs containing 2’-O-methyl 3’phosphorothioate or 2’-O-methyl 3’thioPACE
drastically improved gene editing. In Hendel et al., enhanced gene editing was seen
whether the chemically modified sgRNA was delivered with Cas9 mRNA or as a
complex with the RNP. The addition of a 2’-O-methyl group has also been shown to
improve gene editing in HEK293 cells4 and in vivo in mice17. The addition of the
3’phosphorothioate group has also been shown to reduce the innate immune response in
primary human cells7,18.
Although chemically modified sgRNAs have been demonstrated to improve Cas9
editing in primary hematopoietic stem cells and primary T cells, no study has investigated
if similar results occur in primary hepatocytes. In this study, we delivered CRISPR-Cas9
RNPs complexed with chemically modified sgRNAs containing 2’-O-methyl and 2’-O-
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methyl 3’phosphorothioate into liver-derived cell lines and primary liver cells to evaluate
if they improve the efficacy of Cas9 genome editing.
4.2 MATERIALS AND METHODS
CRISPR sgRNA design
The sgRNAs for transfection in mouse cells were designed using the Benchling
CRISPR Guide RNA Design Tool (benchling.com/crispr). The unmodified and
chemically modified sgRNA sequences for the mouse genome are shown in Table 4.1.
The sgRNAs Hepa 1-6 cells and primary mouse and human hepatocytes were obtained
from TriLink Biotechnologies.

Table 4.1 Sequences of synthetic sgRNA and locations of chemical modifications.
(2’OMe) indicates 2'-O-methyl modifications, and (ps) indicates phosphorothioate
nucleoside modifications. No additional modifications were made to the sgRNAs
other than those shown below.
Modification
Unmodified

M-modified

MS-modified

Sequence
5’ CAA CCC AGA AGG UCA CCG AGG UUU UAG AGC UAG
AAA UAG CAA GUU AAA AUA AGG CUA GUC CGU UAU CAA
CUU GAA AAA GUG GCA CCG AGU CGG UGC UUU U 3’
5’ 2’OMe (CAA) CCC AGA AGG UCA CCG AGG UUU UAG
AGC UAG AAA UAG CAA GUU AAA AUA AGG CUA GUC
CGU UAU CAA CUU GAA AAA GUG GCA CCG AGU CGG
UGC 2’OMe(UUU) U 3’
5’ 2’OMe(C(ps)A(ps)A(ps)) CCC AGA AGG UCA CCG AGG UUU
UAG AGC UAG AAA UAG CAA GUU AAA AUA AGG CUA
GUC CGU UAU CAA CUU GAA AAA GUG GCA CCG AGU
CGG UGC 2’OMe(U(ps)U(ps)U(ps)) U 3’
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Cell culture and electroporation
Hepa 1-6 cells (ATCC) and primary hepatocytes were cultured at 37°C in a
humidified incubator with 5% CO2 and ambient oxygen levels. Hepa 1-6 cells were
maintained in DMEM (Gibco) supplemented with 10% FBS, 4 mM L-glutamine, and 1X
antibiotic-antimycotic. Cryopreserved C57BL/6J plateable mouse hepatocytes (Product
code: MBCP01, Lonza) isolated from 4-month-old male mice were thawed using Rodent
and Monkey Cryopreserved Hepatocyte Thawing Medium (Lonza) according to the
manufacturer’s instructions. Cryopreserved mouse hepatocytes were maintained in
Hepatocyte Plating Medium (Lonza) in 6-well Corning Primaria plates. Following cell
attachment, the media was replaced with Hepatocyte Maintenance Medium (Lonza). At
24 hours after electroporation, 0.25 mg/mL Corning Matrigel basement membrane matrix
was added as an overlay, and hepatocytes were cultured for 48 more hours before
harvesting genomic DNA.
Cas9 RNPs were delivered to Hepa 1-6 cells by electroporation with a 4DNucleofector X Unit (Lonza). To form the RNP, the SpCas9 protein was incubated with
the Hpd-targeting sgRNA for 20 minutes at room temperature before delivery. Hepa 1-6
cells were electroporated using the SF Cell Line 4D-Nucleofector solution (Lonza) with
4D-Nucleofector program CM-138. Conditions for electroporation were: 20 µL SF
nucleofection buffer; 1.2 x 105 cells; 0.5 µL of 20 µg/µL sgRNA; and 1.7 µL of 61 µM
3NLS SpCas9. Delivery efficiency for Hepa 1-6 cells was determined by separately
electroporating cells with 0.4 µL of 1 µg/µL pmaxGFP (Lonza) and analyzing cells using
a Guava Flow Cytometer at 24 hours after electroporation. Primary mouse hepatocytes
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were electroporated using Lonza Nucleofector 2b (program T-028), Mouse/Rat
Hepatocyte Nucleofector solution (Lonza), and electroporation conditions: 100 µL
Mouse/Rat Hepatocyte Nucleofector solution; 1.2 x 106 cells; 1.5 µL of 20 µg/µL
sgRNA; and 4.9 µL of 61 µM 3NLS SpCas9. Delivery efficiency in primary mouse
hepatocytes was estimated by electroporating cells with CleanCap eGFP mRNA and
analyzing the percentage of GFP-positive cells using phase and fluorescence microscopy
images 24 hours after electroporation
Measuring allele alterations using TIDE
Genomic DNA from electroporated cells was extracted using QuickExtract DNA
Extraction Solution (Lucigen) according to the manufacturer’s instructions. Primers used
for PCR amplification of target sites are listed in Table 3.3. PCR was performed with
AccuPrime Taq DNA Polymerase (Invitrogen) following the manufacturer’s instructions
for 35 cycles (94°C for 30 seconds; 57°C for 30 seconds; 68°C for 1 minute). Amplicons
were purified by QIAquick PCR Purification kit (Qiagen) or Agencourt AMPure XP
beads (Beckman Coulter) and then subjected to Sanger sequencing (Eurofins Genomics).
Sanger sequence reads were uploaded to Tracking of Indels by Decomposition (TIDE)19
and compared to a control sequence to quantify Cas9 generated indels at the target site.
Statistical Analysis
The data generated in each experiment were imported into Prism 8.0 (GraphPad
Software). One-way ANOVA and Tukey’s multiple comparisons tests were performed to
determine the statistical significance of means for comparing on-target indels for Hepa 1-
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6 and primary mouse hepatocyte experiments. P-values < 0.05 were considered
significant.
4.3 RESULTS
Hepa 1-6 cells were electroporated with chemically modified synthetic sgRNA
complexed with Cas9 protein. The modifications tested were the addition of 2'-O-methyl
(M-sgRNA) or 2'-O-methyl phosphorothioate (MS-sgRNA) linkages to the first and last
three consecutive nucleotides on the 5’ and 3’ ends of the sgRNA, respectively (Figure
4.1). In addition to Cas9, Hepa 1-6 cells were electroporated with pmax GFP plasmid
DNA to determine transfection efficiency. Average transfection efficiency was >77% as
measured by flow cytometry (Table 4.2).

Figure 4.1 Schematic of chemical modifications in the sgRNA structure.
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Table 4.2 Electroporation efficiency in Hepa 1-6 cells. S1-S3 refer to Cas9
comparison transfections performed in Hepa 1-6 cells (Figure 4.1). Electroporation
efficiency was quantified by electroporation of Hepa 1-6 cells with pmaxGFP vector
(Lonza) and measuring fluorescence by Millipore Guava easyCyte HT Flow
Cytometer at 24-hours post electroporation.

Experiment
S1
S2
S3

Electroporation Efficiency
53.6%
92.4%
87.1%

Higher gene editing efficiency was observed in cells treated with the MSmodified sgRNA than the unmodified sgRNA (Figure 4.2) in Hepa 1-6 cells
electroporated with Cas9 RNP complexes (mean 82.6 and 94.7, respectively, p = 0.0047).
In contrast, there was no significant difference in indels between unmodified and Mmodified sgRNA (mean 82.6 and 87.5, respectively, p = 0.2482), which indicates the
addition of phosphorothioate combined with the 2'-O-methyl provides enhanced gene
editing in Hepa 1-6 cells.
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Figure 4.2 On-target indels for unmodified and chemically modified synthetic
sgRNA co-transfected along with Cas9 protein. Dots represent different
electroporation experiments, and horizontal bars represent the means (n = 3).
Asterisks indicate statistical significance, ** is for p < 0.01. Mock samples were
electroporated with pmaxGFP.
sgRNA was repeated in primary cryopreserved mouse hepatocytes. Transfection
efficiency was determined by delivering eGFP mRNA to mouse hepatocytes. The
average transfection efficiency for treated hepatocytes was >79% (Table 4.3). Average
editing efficiencies were higher than 89% for all hepatocytes treated with Cas9 RNPs
(Figure 4.2). The highest average editing efficiency occurred in hepatocytes treated with
the M-modified sgRNA, while hepatocytes treated with MS-modified sgRNA had a
slightly lower editing efficiency (mean 92.0 and 90.9, respectively, p = 0.9900).
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Curiously, no significant difference in on-target editing was observed between
unmodified and chemically modified sgRNA (p = 0.9133 for Unmodified vs. M-modified
and p = 0.9843 for Unmodified vs. MS-modified).
Table 4.3 Electroporation efficiency and viability in cryopreserved mouse
hepatocytes following electroporation. P1-P3 refer to electroporation experiments
performed in mouse hepatocytes following thawing (Figure 3.3). Electroporation
efficiency was quantified by counting the percentage of GFP positive cells using
microscopy.
Experiment
SP1
SP2
SP3

Electroporation Efficiency
82.7%
79.4%
74.5%

Figure 4.3 On-target indels for unmodified and chemically modified sgRNA
electroporated along with Cas9 protein into cryopreserved primary mouse
hepatocytes. Dots represent different electroporation experiments, and horizontal bars
represent the means (n = 3). Mock samples were electroporated with eGFP mRNA.
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4.4 DISCUSSION
We tested chemical modifications to the gRNA and found that the addition of 2’O-methyl 3’phosphorothioate did improve gene editing in Hepa 1-6 cells. However, the
same modification did not significantly enhance gene editing in primary hepatocytes. Our
results contrast with the study by Hendel et al. that found chemical modifications in
sgRNA significantly increased Cas9 editing in primary T cells and CD34+ HSPCs6. The
results here indicate that sgRNA used for gene editing in hepatocytes do not require the
same chemical protection.
In Hendel et al., unmodified and chemically modified sgRNA targeting ILR2G
were codelivered with Cas9 mRNA into human hematopoietic stem cells by
electroporation. Treatment with the unmodified sgRNA resulted in low gene editing
frequencies (~7.0%). In contrast, cells treated with the MS-modified sgRNA had
drastically higher gene editing frequencies (~87%). The authors repeated this experiment
but delivered unmodified and modified sgRNA at 4 and 8 hours later and found the
unmodified sgRNA resulted in comparable rates of gene editing activity as the
chemically modified sgRNA (~80-90%). This indicates that when complexed with the
Cas9 protein, sgRNA is much less susceptible to degradation6. The authors tested
delivery of the unmodified sgRNA complexed with the Cas9 protein in K562 cells and
did find higher gene editing frequencies than in cells treated with unmodified sgRNA and
Cas9 mRNA (35.9% vs. 7.0%). Editing frequency was still much lower than with Cas9
proteins complexed with MS-modified sgRNA (81.0%).
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In contrast, we observed comparable levels of gene editing in primary mouse
hepatocytes when using Cas9 RNPs complexed with either unmodified, M-modified, or
MS-modified sgRNA. This indicates that in primary mouse hepatocytes, the Cas9 RNP
complex provides sufficient protection from nucleases for the sgRNA. We did observe
that the MS-modified sgRNA provided significantly higher levels of gene editing than the
unmodified sgRNA in Hepa 1-6 cells. RNase activity may be higher in Hepa 1-6 cells
than primary hepatocytes, which could explain the discrepancy in gene editing between
the cell lines.
4.5 CONCLUSION
The addition of a 2'-O-methyl and a 3’phosphorothioate linkage significantly
increased on-target editing in Hepa 1-6 cells when complexed with the Cas9 protein. In
cryopreserved primary mouse hepatocytes, no significant difference between the editing
activity of Cas9 complexed with chemically modified and unmodified sgRNA was
observed. The same modifications required for efficient Cas9 editing in HSPCs and T
cells are not necessary for editing in primary hepatocytes.
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CHAPTER FIVE
SPECIFIC AIM 2.2: DEVELOP A PIPELINE FOR NEXT-GENERATION
SEQUENCING ANALYSIS OF CAS9 SPECIFICITY AND APPLY IT TO THE
EXTENT THAT HIGH FIDELITY CAS9 RETAINS EFFICIENCY WHILE
REDUCING OFF-TARGET GENE EDITING
5.1 INTRODUCTION
A significant limitation for CRISPR-Cas9 genome editing is off-target
mutagenesis at sequences highly similar to the target site1–3. The targeting efficiency of
Cas9 is determined by the 20-nucleotide sequence of gRNA bound to the protein and the
presence of a PAM sequence adjacent to the target site. Mismatches between the gRNA
and the cleavage site can lead to off-target editing. The Cas9 system strongly tolerates
mismatches with off-target editing, having been observed at DNA sequences with up to
five base pair mismatches with the gRNA sequence1,4,5. Off-target effects remain a
serious concern as they can lead to lethal mutations, loss of gene function, or
development of cancer 2,6. Two strategies for reducing off-target editing are delivering
transient forms of Cas9 and using Cas9 variants with improved specificity6,7.
Prolonged expression of Cas9 can lead to increased indel formation at off-target
sites1. Cas9 delivered as plasmid DNA into cells can integrate into the host genome
leading to lengthy, stable expression of Cas9. In studies that have delivered Cas9 as
plasmid DNA into cells, off-target editing was noted to be as high or even higher than
editing at the intended target site1,8. Transient expression of Cas9, such as from mRNA or
RNP, could reduce off-target editing by limiting the presence of Cas9 in the cell. A
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comparison study found that the off-target to on-target editing ratio was reduced 28-fold
in cells treated with RNPs compared to cells treated with Cas9 pDNA9. Other studies
have also reported decreases in off-target editing when delivering Cas9 as RNPs or
mRNA10–12.
Modified Cas9 variants have been developed to improve precise genome
editing13,14. Enhanced Cas9 variants are made by introducing mutations that weaken the
protein’s ability to bind to a non-target DNA sequence. The first Cas9 variant designed to
improve specificity is the eSpCas9.13 The eSpCas9 was generated by introducing
mutations that substituted alanine in place of positive residues in the Cas9 structure.
Reducing the positive charge of the protein prevents it from readily binding to the
negatively charged DNA. In HEK293 cells, this variant was shown to reduce off-target
editing at most off-target sites but also reduced on-target editing as well13. In Vakulskas
et al., a wide array of mutated Cas9 variants were screened, and a single point mutation,
p.R691A, was found to reduce off-target editing without sacrificing on-target editing
efficiency14. Several studies have shown that the HiFi Cas9-R691A (HiFi Cas9) variant
reduces off-target activity while maintaining robust on-target gene editing in CD34+
HSPCs14–16. The HiFi Cas9 has not yet been examined in primary mouse hepatocytes for
precise genome editing.
To determine if different forms of Cas9 expression can reduce off-target editing in
hepatocytes, we performed deep sequencing on DNA isolated from hepatocytes and liverderived cells electroporated with different variants of Hpd-targeting Cas9. Cells were
treated with either Cas9 pDNA, mRNA, or RNP. In addition, some samples were treated
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with the HiFi Cas9 variant to determine if it reduces off-target editing in primary mouse
hepatocytes.
5.2 MATERIALS AND METHODS
Hepatocyte isolation
Animal care and experiments were all under the guidelines and approved
protocols of the Institutional Animal Care and Use Committee at Clemson University.
Hepatocytes were isolated from anesthetized male C57BL/6J mice aged 8-10 weeks old
using a three-step perfusion procedure described in17. Briefly, the inferior vena cava was
cannulated and perfused with three solutions. The final solution to complete in situ
digestion consisted of EBSS with Ca2+/Mg2+ supplemented with 10 mM HEPES pH 7.4
and 0.094 Wunsch units/mL Liberase (Sigma Aldrich). The liver was dissected carefully
without injuring the capsule and disrupted using scissors. The dissociated cells were then
collected and added to ice-cold high glucose Dulbecco’s Modified Eagle’s Medium
(DMEM, Gibco) supplemented with 10% FBS. The cells were pelleted by centrifugation
and washed several times. Electroporation was conducted using isolated hepatocytes with
a yield of 10-40 x 106 cells and 80% cell viability (measured by trypan blue staining).
CRISPR sgRNA design and DNA constructs
The sgRNAs for transfection in mouse and Hepa 1-6 cells were designed using
the Benchling CRISPR Guide RNA Design Tool (benchling.com/crispr). Sequences for
sgRNAs targeting mouse Hpd are shown in Table 3.1. The sgRNAs transfected into Hepa
1-6 cells and primary mouse hepatocytes were obtained from TriLink Biotechnologies or
Horizon Discovery Biosciences.
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The pX330-U6-Chimeric_BB-CBh-hSpCas9 plasmid, a gift from F. Zhang
(Addgene plasmid #42230), was transformed into DH5α competent cells (Invitrogen).
Plasmid DNA was extracted using the Qiagen midi prep protocol. Using standard cloning
procedures, annealed oligonucleotides containing guide sequences targeting the mouse
Hpd locus (Eurofins Genomics) were ligated into the pX330-U6-Chimeric_BB-CBhhSpCas9 plasmid. Plasmids encoding Hpd-aiming CRISPR-Cas9 were evaluated in NIH
3T3 cells.
For constructing the pX330-U6-Chimeric_BB-CBh-hSpCas9Δ179-595 plasmid
(hereafter Cas9 plasmid DNA), 416 bp gRNA scaffold located between the NdeI sites at
179 and 595 was removed by restriction enzyme NdeI treatment of the pX330-U6Chimeric_BB-CBh-hSpCas9 plasmid. Briefly, 2.5 µg of the plasmid DNA was digested
with 25 units of NdeI (New England BioLabs) at 37oC for 30 minutes in CutSmart
Buffer. The enzyme was inactivated by heating for 20 minutes at 60oC. The resulting
8090 bp and 416 bp fragments were separated on 1.5 % agarose gel containing Ethidium
Bromide. The DNA was visualized under UV light, and the larger 8090 bp fragment was
excised for purification with QIAquick Gel Extraction Kit (Qiagen). Next, 25 ng of the
purified linear fragment was ligated with T4 DNA ligase enzyme (New England
BioLabs) for 4 hours at room temperature, then transformed into DH5α cells. The Cas9
plasmid DNA was isolated using the QIAprep Spin Miniprep kit (Qiagen), and the
deletion of the 416 bp fragment was verified using agarose gel electrophoresis.
Cell culture and electroporation
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Hepa 1-6 cells (ATCC) and primary hepatocytes were cultured at 37°C in a
humidified incubator with 5% CO2 and ambient oxygen levels. Cells were maintained in
DMEM (Gibco) supplemented with 10% FBS, 4 mM L-glutamine, and 1X antibioticantimycotic. Cryopreserved C57BL/6J plateable mouse hepatocytes (Product code:
MBCP01, Lonza) isolated from 4-month-old male mice were thawed using Rodent and
Monkey Cryopreserved Hepatocyte Thawing Medium (Lonza) according to the
manufacturer’s instructions. Cryopreserved and freshly isolated mouse hepatocytes were
maintained in Hepatocyte Plating Medium (Lonza) in 6-well Corning Primaria plates.
Following cell attachment, the media was replaced with Hepatocyte Maintenance
Medium (Lonza). At 24 hours after electroporation, 0.25 mg/mL Corning Matrigel
basement membrane matrix was added as an overlay.
Hepa 1-6 cells were electroporated with a 4D-Nucleofector X Unit (Lonza). For
reactions with Cas9 RNPs, the SpCas9 RNP was incubated with the Hpd targeting
sgRNA for 20 minutes at room temperature. Hepa 1-6 cells were resuspended in SF Cell
Line 4D-Nucleofector solution (Lonza) and electroporated with the 4D-Nucleofector
program CM-138. The Hepa1-6 electroporation conditions were as follows: 20 µL SF
nucleofection buffer; 1.2 x 105 cells; 0.5 µL of 20 µg/µL sgRNA; and 0.76 µL of 1.32
µg/µL Cas9 pDNA, 1 µL of 1 µg/µL CleanCap Cas9 mRNA (Product code: L-72061000, TriLink Biotechnologies), 1.7 µL of 61 µM 3NLS SpCas9, or 1.7 uL of 61µM
3NLS HiFi SpCas9 (Product code: 1078728, Integrated DNA technologies). For reactions
with Cas9 RNPs, the SpCas9 RNP was incubated with the Hpd targeting sgRNA for 20
minutes at room temperature. For cell lines, delivery efficiency was determined by
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separately electroporating cells with 0.4 µL of 1 µg/µL pmaxGFP (Lonza) and analyzing
cells using a Guava Flow Cytometer 24 hours after electroporation. Primary mouse
hepatocytes were electroporated using Lonza Nucleofector 2b (program T-028),
Mouse/Rat Hepatocyte Nucleofector solution (Lonza), and electroporation conditions:
100 µL Mouse/Rat Hepatocyte Nucleofector solution; 1.2 x 106 cells; 1.5 µL of 20 µg/µL
sgRNA; and 4 µL of 1 µg/µL CleanCap Cas9 mRNA, 4.9 µL of 61 µM 3NLS SpCas9,
4.9 µL of 61 µM 3NLS HiFi SpCas9. The delivery efficiency in primary mouse
hepatocytes was estimated by electroporating cells with CleanCap eGFP mRNA and
analyzing the percentage of GFP-positive cells using phase and fluorescence microscopy
images 24 hours after electroporation. Hepatocytes were stained with trypan blue and
counted for cell viability using a hemocytometer.
Identification and ranking of off-target sites
Potential off-target sites for the Hpd-targeting sgRNA design were identified
using CRISPR-Off-target Sites with Mismatches, Insertions, and Deletions (COSMID)18.
The CRISPR guide sequence was entered into the program, and a list of related
sequences with up to three or fewer base mismatches or sites containing a single base
insertion or deletion were considered for potential off-target sites. COSMID generated a
list of these sites adjacent to an NRG or NGG PAM site. Sites were then ranked by
lowest score and priority given to NGG mismatches over NRG mismatches. We selected
ten off-target sites for deep sequencing experiments (Table 5.1).
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Table 5.1 The on-target site within Hpd and ten off-target sites generated by
COSMID for potential off-target editing.
Site
Name
ON

Sequence

Location

CAACCCAGAAGGTCACCGAGTGG

OF1

AATCCCATAAGATCACCGAGAGG

OF2

AATCCCAGCAGGGCACCGAGGGG

OF3

CAGCCCAGAAGATCAACGAGGGG

OF4

CCACTCAGAATGTCACCGAGAGG

OF5

Gene

Chr5:123181875- HPD
123181897
Chr3:3609956HNF4G
3609978
Chr4:117306960117306982
Chr18:6297797362977995
Chr8:125338259125338281

RNF220

CCACCCAGCAGGGCACCGAGAGG

Chr7:6772298167723003

TTC23

OF6

AAAGACAGAAGGTCACAGAGAGG

Chr6:6634104866341070

Noncoding

OF7

AAAGCCAGAAGGTGCCCGAGTGG

Chr8:1100516911005191

IRS2

OF8

GAGCCCAGCAGGTCACAGAGAGG

Chr7:7313847573138497

Noncoding

OF9

GAAGCCAGAAAGTCACAGAGAGG

Chr7:136293426- Non136293448
coding

OF10

TAACTCCGAAGGTCACCAAGAGG

Chr13:43512665- Non43512687
coding

Measuring allele alterations by deep sequencing
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NAPG
Noncoding

For deep sequencing analysis of Hepa 1-6 cells and cryopreserved mouse
hepatocytes, we amplified the on- and off-target sites from extracted genomic DNA by
two rounds of PCR as described in19. The first round of PCR added P5 and P7 adaptors to
the specific genomic sequence (Table 5.2). The second round of PCR was performed on
individual amplicons using primers described previously19 containing adapter sequences
from the first PCR and a unique barcode sequence for samples in the reverse primer
(Table 5.3). PCR reactions for preparing samples for deep sequencing were performed
using HotStart Taq DNA Polymerase (New England Biolabs). For the first round of PCR,
the reactions were performed with an annealing temperature of 63°C for 35 cycles. The
second round of PCR was performed using the PCR product from the first as a template
with an annealing temperature of 65°C for 35 cycles. Barcoded amplicons were purified
using the QIAquick PCR Purification kit. The samples were then pooled in equal
amounts and resolved on a 1% agarose gel to separate the amplicons from primer dimers.
The second PCR amplicon pool was extracted from the gel using the QIAquick Gel
Extraction kit (Qiagen). The purified samples were then sequenced by 2 x 250 paired-end
sequencing on an Illumina MiSeq platform. Indels were then quantified by a custom
script available at https://github.com/piyuranjan/NucleaseIndelActivityScript.
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Table 5.2 First-step PCR primers for amplification of target sites for Cas9 gene
editing.
Forward
Hpd
OF1
OF2
OF3
Reverse
Hpd
OF1
OF2
OF3

Adapter
TCTACAGTCCGACGATCA
TCTACAGTCCGACGATCA
TCTACAGTCCGACGATCA
TCTACAGTCCGACGATCA
Adapter
GACGTGTGCTCTTCCGATC
GACGTGTGCTCTTCCGATC
GACGTGTGCTCTTCCGATC
GACGTGTGCTCTTCCGATC

Gene Specific
CTCCCCTCGCACTAGCCAAT
CCAGTGAGCAGACTCCTCTTTC
ATGCAGATGCTTTAGACCCAGTCC
TTTGAGTCCTTCGCTTCCCGTAG
Gene Specific
TAGCCAAAGATGGGAGCAGGG
CACGAGGGAATTCAGGGTCTTG
TCCTAGCCTGAGGTGAACTCTCT
GCAGGGGATTGACCCACAAG

Table 5.3 Primer sequences for second-step PCR and custom sequencing primers for
MiSeq. Index sequences are highlighted in red.
Primer
Index Read
Read 1
Read 2

Sequence
GATCGGAAGAGCACACGTCTGAACTCCAGTCACAT
TCTACACGTTCAGAGTTCTACAGTCCGACGATCA
TGTGACTGGAGTTCAGACGTGTGCTCTTCCGATC

FWD Primer

AATGATACGGCGACCACCGAGATCTACACGTTCAGAGTTCTACAGTCCGACGATCA

Sample

REV Primer

H1A1

CAAGCAGAAGACGGCATACGAGATAACTCTCGATGTGACTGGAGTTCAGACGTGTGCTCTTCCGATC

H1B1

CAAGCAGAAGACGGCATACGAGATACTATGTCATGTGACTGGAGTTCAGACGTGTGCTCTTCCGATC

H1C1

CAAGCAGAAGACGGCATACGAGATAGTAGCGTATGTGACTGGAGTTCAGACGTGTGCTCTTCCGATC

H1D1

CAAGCAGAAGACGGCATACGAGATCAGTGAGTATGTGACTGGAGTTCAGACGTGTGCTCTTCCGATC

H1E1

CAAGCAGAAGACGGCATACGAGATCGTACTCAATGTGACTGGAGTTCAGACGTGTGCTCTTCCGATC

H1F1

CAAGCAGAAGACGGCATACGAGATCTACGCAGATGTGACTGGAGTTCAGACGTGTGCTCTTCCGATC

H1G1

CAAGCAGAAGACGGCATACGAGATGGAGACTAATGTGACTGGAGTTCAGACGTGTGCTCTTCCGATC

H1H1

CAAGCAGAAGACGGCATACGAGATGTCGCTCGATGTGACTGGAGTTCAGACGTGTGCTCTTCCGATC

H1Mock

CAAGCAGAAGACGGCATACGAGATGTCGTAGTATGTGACTGGAGTTCAGACGTGTGCTCTTCCGATC

H2A1

CAAGCAGAAGACGGCATACGAGATTAGCAGACATGTGACTGGAGTTCAGACGTGTGCTCTTCCGATC

H2B1

CAAGCAGAAGACGGCATACGAGATTCATAGACATGTGACTGGAGTTCAGACGTGTGCTCTTCCGATC

H2C1

CAAGCAGAAGACGGCATACGAGATTCGCTATAATGTGACTGGAGTTCAGACGTGTGCTCTTCCGATC

H2D1

CAAGCAGAAGACGGCATACGAGATAAGTCGAGATGTGACTGGAGTTCAGACGTGTGCTCTTCCGATC

H2E1

CAAGCAGAAGACGGCATACGAGATATACTTCGATGTGACTGGAGTTCAGACGTGTGCTCTTCCGATC

H2F1

CAAGCAGAAGACGGCATACGAGATAGCTGCTAATGTGACTGGAGTTCAGACGTGTGCTCTTCCGATC

H2H1

CAAGCAGAAGACGGCATACGAGATCATAGAGAATGTGACTGGAGTTCAGACGTGTGCTCTTCCGATC
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H2H1

CAAGCAGAAGACGGCATACGAGATCGTAGATCATGTGACTGGAGTTCAGACGTGTGCTCTTCCGATC

H2Mock

CAAGCAGAAGACGGCATACGAGATCTCGTTACATGTGACTGGAGTTCAGACGTGTGCTCTTCCGATC

Hepa1-6 Untr

CAAGCAGAAGACGGCATACGAGATGCGCACGTATGTGACTGGAGTTCAGACGTGTGCTCTTCCGATC

P1A1

CAAGCAGAAGACGGCATACGAGATGGTACTATATGTGACTGGAGTTCAGACGTGTGCTCTTCCGATC

P1A2

CAAGCAGAAGACGGCATACGAGATGTATACGCATGTGACTGGAGTTCAGACGTGTGCTCTTCCGATC

P1B1

CAAGCAGAAGACGGCATACGAGATTACGAGCAATGTGACTGGAGTTCAGACGTGTGCTCTTCCGATC

P1B2

CAAGCAGAAGACGGCATACGAGATTCAGCGTTATGTGACTGGAGTTCAGACGTGTGCTCTTCCGATC

P1C1

CAAGCAGAAGACGGCATACGAGATTCGCTACGATGTGACTGGAGTTCAGACGTGTGCTCTTCCGATC

P1C2

CAAGCAGAAGACGGCATACGAGATACCTACTGATGTGACTGGAGTTCAGACGTGTGCTCTTCCGATC

P1Mock

CAAGCAGAAGACGGCATACGAGATAGCGCTATATGTGACTGGAGTTCAGACGTGTGCTCTTCCGATC

P2A1

CAAGCAGAAGACGGCATACGAGATAGTCTAGAATGTGACTGGAGTTCAGACGTGTGCTCTTCCGATC

P2A2

CAAGCAGAAGACGGCATACGAGATCATGAGGAATGTGACTGGAGTTCAGACGTGTGCTCTTCCGATC

P2B1

CAAGCAGAAGACGGCATACGAGATCTAGCTCGATGTGACTGGAGTTCAGACGTGTGCTCTTCCGATC

P2B2

CAAGCAGAAGACGGCATACGAGATCTCTAGAGATGTGACTGGAGTTCAGACGTGTGCTCTTCCGATC

P2C1

CAAGCAGAAGACGGCATACGAGATGAGCTCATATGTGACTGGAGTTCAGACGTGTGCTCTTCCGATC

P2C2

CAAGCAGAAGACGGCATACGAGATGGTATGCTATGTGACTGGAGTTCAGACGTGTGCTCTTCCGATC

P2Mock

CAAGCAGAAGACGGCATACGAGATGTATGACGATGTGACTGGAGTTCAGACGTGTGCTCTTCCGATC

P3A1

CAAGCAGAAGACGGCATACGAGATTAGACTGAATGTGACTGGAGTTCAGACGTGTGCTCTTCCGATC

P3A2

CAAGCAGAAGACGGCATACGAGATTCACGATGATGTGACTGGAGTTCAGACGTGTGCTCTTCCGATC

P3B1

CAAGCAGAAGACGGCATACGAGATTCGAGCTCATGTGACTGGAGTTCAGACGTGTGCTCTTCCGATC

P3B2

CAAGCAGAAGACGGCATACGAGATACCTAGTAATGTGACTGGAGTTCAGACGTGTGCTCTTCCGATC

P3C1

CAAGCAGAAGACGGCATACGAGATACGTACGTATGTGACTGGAGTTCAGACGTGTGCTCTTCCGATC

P3C2

CAAGCAGAAGACGGCATACGAGATATATCGCGATGTGACTGGAGTTCAGACGTGTGCTCTTCCGATC

P3Mock

CAAGCAGAAGACGGCATACGAGATCACGATAGATGTGACTGGAGTTCAGACGTGTGCTCTTCCGATC

Primary Untr

CAAGCAGAAGACGGCATACGAGATCGTATCGCATGTGACTGGAGTTCAGACGTGTGCTCTTCCGATC

IB1

CAAGCAGAAGACGGCATACGAGATCTGCGACTATGTGACTGGAGTTCAGACGTGTGCTCTTCCGATC

IB2

CAAGCAGAAGACGGCATACGAGATGCTGTAACATGTGACTGGAGTTCAGACGTGTGCTCTTCCGATC

IC1

CAAGCAGAAGACGGCATACGAGATGGACGTTAATGTGACTGGAGTTCAGACGTGTGCTCTTCCGATC

IC2

CAAGCAGAAGACGGCATACGAGATGGTCGTAGATGTGACTGGAGTTCAGACGTGTGCTCTTCCGATC

Isolated Untr

CAAGCAGAAGACGGCATACGAGATTAAGTCTCATGTGACTGGAGTTCAGACGTGTGCTCTTCCGATC

For subsequent next-generation sequencing experiments in the freshly isolated
mouse hepatocytes, on- and off-target sites were amplified using the rhAmpSeq CRISPR
Library Kit (Product Code: 10007318, Integrated DNA Technologies) according to the
manufacturer’s instructions. Briefly, the rhAmpSeq Mix 1 and rhAmpSeq forward and
reverse assay primer pools were designed and synthesized by Integrated DNA
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Technologies. Genomic DNA was amplified using a thermal cycler with the following
conditions: 95°C for 10 minutes; 10 cycles of 95°C for 15 seconds and 61°C for 4
minutes; and 99.5°C for 15 minutes. Products of rhAmp PCR products were cleaned up
using Sera-Mag Select beads (Cytiva). For the cleanup, 30 uL of beads were added to
PCR products and incubated at room temperature for 10 minutes. Beads were then
collected using a magnetic plate, and the supernatant discarded. The beads were washed
twice with 200 uL of 80% ethanol and then dried at room temperature for 3 minutes. The
beads were then resuspended in 15 uL of IDTE pH 8.0 (Integrated DNA Technologies) to
elute the DNA. Next, 11 uL of cleaned PCR product was used for the second round of
PCR using rhAmpSeq Library Mix 2 and Indexing Primers i5 and i7. The following
cycling conditions were used for the second PCR: 95°C for 3 minutes; 18 cycles of 95°C
for 15 seconds, 60°C for 30 seconds, and 72°C for 1 minute; 72°C for 1 minute. The
second-round PCR products were cleaned up using Sera-Mag Select beads. Samples were
pooled together, and the library was sequenced by 2 x 250 paired-end sequencing on an
Illumina MiSeq platform. Fastq files from the MiSeq run were uploaded to IDT’s
rhAmpSeq CRISPR Analysis Tool and merged. Indel quantification was then performed
by IDT’s data analysis tool, CRISPRAltRations, with the default settings.
Statistical Analysis
The data generated in each experiment were imported into Prism 8.0 (GraphPad
Software). Two-way ANOVA tests were performed on the deep sequencing data for the
on- and off-target analysis. Unpaired t-tests were performed to compare indels between
the different samples. P-values < 0.05 were considered significant.
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5.3 RESULTS
Hepa 1-6 cells were electroporated with Cas9 mRNA, Cas9 RNP, and HiFi Cas9
RNP with Hpd-targeting sgRNA. The off-target activity was assessed at three COSMIDpredicted sites using deep sequencing on an Illumina MiSeq (Figure 5.1). We detected
low indels (<2%) at off-target sites OF1 and OF2, whereas high off-target indels (>7.5%)
were detected at OF3 in Hepa 1-6 cells electroporated with Hpd-CRISPR-Cas9.
Electroporation of Cas9 RNP resulted in slightly lower indels at OF3 than Cas9 mRNA
though not statistically significant (mean 8.1% and 17.8%, respectively, p = 0.6791),
while HiFi Cas9 RNP provided similar off-target indels as WT RNP. Although the
number of deep sequencing reads for the on-target site were low (Table 5.3), the on-target
editing efficiency was consistent with the TIDE results obtained using Sanger sequencing
(see Figure 3.2). In contrast, we received high sequencing reads for the off-target sites,
which is critical for accurately detecting rare off-target editing events.
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Figure 5.1 On- and off-target Cas9 activity in electroporated Hepa 1-6 cells. Onand off-target indels for Hepa 1-6 cells treated with Cas9 mRNA, WT RNP, and HiFi
RNP. Indels were assessed using deep sequencing. Dots represent different
electroporation experiments, and horizontal bars represent the means (n = 3). Mock
samples were electroporated with pmaxGFP.
Despite the low deep sequencing reads at the on-target site (Table 5.5), we
obtained similar on-target indels from the deep sequencing and TIDE analysis (see Figure
3.3). We observed low indels at OF1 and OF2, while OF3 showed high indels (Figure
5.2) in primary mouse hepatocytes electroporated with Cas9 mRNA (31.2%) and WT
RNP (16.7%). Cryopreserved mouse hepatocytes electroporated with HiFi Cas9 RNP
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showed a 5-fold reduction in off-target indels at OF3 compared to WT Cas9 RNP though
not statistically significant (mean 2.9% and 16.7%, respectively, p = 0.6511).
For deep sequencing analysis of Cas9 efficiency and specificity in freshly isolated
mouse hepatocytes, we expanded the number of off-target sites to ten. The deepsequencing data provided low reads for the on-target sites but overall high reads for the
off-target sites (Table 5.6). However, the deep sequencing data’s on-target indels were
consistent with the TIDE analysis for the Cas9 mRNA and RNP (Figure 3.4). The high
on-target indels detected for the mock (eGFP mRNA) are due to the low sequencing
depth. Overall, the deep sequencing data confirmed high levels of on-target gene editing
in hepatocytes electroporated with Cas9 mRNA (80.1%) and RNP (86.9%). Further, most
of these alterations (Figure 5.4) produced by Cas9 mRNA and RNP were frameshift
mutations (mean 53.7% and 76.2%, respectively). Consistent with our results in Hepa 1-6
cells and cryopreserved primary mouse hepatocytes, we observed low levels of indels
(<3%) at all off-target sites except for OF3. However, the levels of indels at OF3 in
freshly isolated mouse hepatocytes were lower than cryopreserved hepatocytes (Figure
5.2). We observed similar indels at OF3 for Cas9 mRNA and RNP (mean 4.6% and
7.9%, respectively, p = 0.7499). Our deep sequencing results suggest that OF3 represents
an actual off-target site.
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Figure 5.2 On- and off-target Cas9 activity in electroporated cryopreserved
primary mouse hepatocytes. Dots represent different electroporation experiments,
and horizontal bars represent the means (n = 3). Mock samples were electroporated
with eGFP mRNA.
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Figure 5.3 Analysis of on- and off-target Cas9 activity in freshly isolated mouse
hepatocytes. Dots represent different electroporation experiments, and horizontal bars
represent the means (n = 3). Mock samples were hepatocytes electroporated with
eGFP mRNA.
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Figure 5.4 Percentage of on-target frameshift mutations in hepatocytes
electroporated with Cas9 mRNA and RNP. Dots represent different electroporation
experiments, and horizontal bars represent the means (n = 3).
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5.4 DISCUSSION
We designed sgRNA targeting the mouse Hpd locus to show proof-of-principle
CRISPR-Cas9-mediated frameshift mutations to disrupt a therapeutic target gene for an
IMD of the liver. Using COSMID, we identified ten potential off-target sites based on
this sgRNA and verified that considerable editing was occurring at one site (OF3). This
site is in the NAPG gene, which codes for gamma-soluble N-ethylmaleimide-sensitive
factor, a protein involved with platelet exocytosis20. In cryopreserved mouse hepatocytes,
we saw high levels of editing (>30%) with the Cas9 mRNA at OF3. The high editing
activity was surprising as mRNA expression of Cas9 is short-lived and should limit the
window of time for off-target editing to occur1. Off-target editing at OF3 was reduced in
cells treated with the WT SpCas9 RNP. Because RNPs do not have to be translated like
mRNA, Cas9 expression is even more transient. Lower editing off-target editing with
RNPs is consistent with previous studies that have delivered Cas9 complexed with
sgRNAs as RNPs9–11. Based on these results, delivery of Cas9 as an RNP reduces offtarget editing in primary mouse hepatocytes.
`

The HiFi Cas9-R691A variant shown to improve gene editing specificity in

electroporated primary human CD34+ HSPCs reduced off-target indels by 5-fold in OF3
compared to WT Cas9 RNPs, though not statistically significant, in primary mouse
hepatocytes without lowering the on-target activity. Therefore, HiFi Cas9 electroporated
as RNPs slightly enhances gene editing specificity compared to WT Cas9 in primary
hepatocytes. In Hepa 1-6 cells, off-target editing between the WT RNP and the HiFi
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variant were comparable (8.1% and 7.5%, respectively). This indicates that the HiFi
variant does not reduce off-target editing in all cell lines.
5.5 CONCLUSION
The Hpd-targeting we designed produced significant off-target editing at only one
of ten sites examined. Cells treated with Cas9 mRNA showed high gene editing activity
at the off-target site OF3, while cells treated with Cas9 RNPs showed reduced off-target
activity. The indels in OF3 were slightly reduced using the HiFi Cas9 variant in
cryopreserved primary mouse hepatocytes. These results indicate that it is critical to
design and screen gRNAs to ensure low to nearly undetectable levels of undesired offtarget modifications to enhance the safety of liver-directed gene-editing therapies.
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CHAPTER SIX
SPECIFIC AIM 3: OPTIMIZE LIPID NANOPARTICLE-MEDIATED
DELIVERY OF MRNA INTO LIVER-DERIVED CELLS AND PRIMARY
HEPATOCYTES
6.1 INTRODUCTION
Lipid nanoparticles (LNPs) are a promising method for in vivo delivery of Cas9.
LNPs are positively charged structures that contain at least one lipid bilayer1. Because
they are positive structures, LNPs can form complexes with negatively charged nucleic
acids and transport them across the membrane. The LNP structure typically consists of a
polar head group and a hydrophobic tail connected by a linker. LNPs have a strong safety
profile and are the most common class of FDA-approved nanostructures for drug
delivery1. Delivery efficiency is typically lower than observed with viral vectors2,3.
Cationic LNPs effectively deliver RNA into cells4, and one study has reported that
encapsulating RNA with a lipid layer can protect against RNases and other degradation
enzymes5. Current challenges with using LNPs for drug delivery include low rates of
transfection6–8 and non-specific delivery9. Commercially available lipid reagents such as
Lipofectamine have been used to deliver Cas9 as plasmid DNA into cells10–12. However,
these kits are associated with high toxicity and typically have low transfection rates13.
Alternatives to commercially available kits are needed for efficient lipid-mediated
delivery of Cas9 for therapeutic gene editing.
Previous studies have evaluated chalcogen-containing bioreducible LNPs for in
vivo delivery of Cas9 mRNA to knockout Pcsk914 and Angptl315. The class of LNPs used
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in these studies was composed of an amine head group and an acrylic tail. In Liu et al.,
Pcsk9 levels were reduced by 20% in the serum of mice treated with these LNPs14. In Qiu
et al., the authors observed that in vivo injection of these bioreducible LNPs complexed
with Cas9 mRNA and sgRNA targeting Angptl3 achieved 31% gene editing in liver
tissue, and this level of gene editing was maintained for at least 150 days after injection15.
These indicate that this class of LNPs is an ideal candidate for liver-targeted in vivo
delivery of Cas9. In this study, we evaluated different formulations of chalcogencontaining, bioreducible LNPs to deliver mRNA into liver-derived cell lines and primary
hepatocytes. Six LNP formulations were tested to deliver eGFP mRNA into HEK293 and
Hepa 1-6 cell lines. The nanoparticles with the highest transfection levels were then
evaluated for transfection efficiency and toxicity in primary mouse hepatocytes. We then
investigated LNP delivery of Cas9 mRNA with Cypor-targeting sgRNA in Hepa 1-6
cells. Cypor is a necessary cofactor for cytochrome p450 (Cyp) enzymes, a class of
enzymes crucial for the metabolism of drugs16. Knockout of Cypor prevents hepatocytes
from converting the drug acetaminophen (APAP) to the hepatotoxic N-acetyl-pbenzoquinone imine (NAPQI). A recent study has demonstrated that mouse hepatocytes
with nonfunctioning Cypor gene have a proliferative advantage over wild-type cells
following in vivo administration of APAP17. Knockout of Cypor can provide hepatocytes
containing therapeutic transgenes protection against APAP and a selective advantage for
repopulating the liver. On-target editing for Cypor will be quantified by the presence of
indels, and viability following transfection will be evaluated by MTT assays.
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6.2 MATERIALS AND METHODS
Hepatocyte isolation
Animal care and experiments were all under the guidelines and approved
protocols of the Institutional Animal Care and Use Committee at Clemson University.
Hepatocytes were isolated from anesthetized male C57BL/6J mice aged 8-10 weeks old
using a three-step perfusion procedure described in18. Briefly, the inferior vena cava was
cannulated and perfused with three solutions. The final solution to complete in situ
digestion consisted of EBSS with Ca2+/Mg2+ supplemented with 10 mM HEPES pH 7.4
and 0.094 Wunsch units/mL Liberase (Sigma Aldrich). The liver was dissected carefully
without injuring the capsule and disrupted using scissors. The dissociated cells were then
collected and added to ice-cold high glucose Dulbecco’s Modified Eagle’s Medium
(DMEM, Gibco) supplemented with 10% FBS. The cells were pelleted by centrifugation
and washed several times.
LNP Transfection in Cell Lines
For HEK293 and Hepa 1-6 cells, 15,000 cells were plated in a 48-well plate 24
hours before adding the LNPs. LNPs were obtained from the lab of Dr. Xu at Tuft’s
University, where they were assembled by synthesized by Michael addition reaction and
ring opening reaction of epoxide with amines in combination with different amines head,
linker compound, and aliphatic chain tail groups19,20. HEK293 cells were cultured with
250 μL of DMEM media containing 10% FBS. For transfection with eGFP mRNA,
LNP/mRNA complexes were prepared by suspending LNPs and mRNA separately into
tubes containing 10 μL of water. The LNPs and mRNA were then combined in one tube
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for a total volume of 20 μL and incubated at room temperature for 15 minutes to form the
complex. The 20 μL mix of LNP and mRNA was then added directly to the wells
containing HEK293 cells. LNPs were complexed with eGFP mRNA at a ratio of 10:1 for
all experiments. Twenty-four hours after adding the LNPs, the cells were harvested by
adding 100 μL of trypsin and incubating for two minutes at 37°C. After adding 500 μL of
DMEM media, cells were transferred to 1.5 mL tubes for flow cytometry. The percentage
of GFP positive cells was quantified with a Guava Flow Cytometer. The same procedure
was used for transfecting Hepa 1-6 cells with eGFP mRNA with one difference. Previous
attempts at transfecting Hepa 1-6 cells with DMEM media containing 10% FBS did not
result in successful transfection. To improve uptake, the media for plated cells was
switched to serum-free DMEM before adding LNPs.
To deliver Cas9 mRNA into Hepa 1-6 cells, CleanCap Cas9 mRNA from TriLink
BioTechnologies and Cypor-targeting sgRNA (Table 5.1) obtained from Horizon
Discovery were incubated together for 10 minutes at room temperature before suspending
in 10 uL of water. The sgRNA sequence was used in a previous study17. The Cas9
mRNA/sgRNA mix was then mixed with LNPs and incubated for 15 minutes at room
temperature. The LNP/RNA complexes were added directly to wells containing the Hepa
1-6 cells.
Table 6.1 Sequence for Cypor-targeting sgRNA
sgRNA Sequence
CYP
TCGTGGGGGTCCTGACCTAC
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LNP Transfection in Primary Hepatocytes
The freshly isolated primary mouse hepatocytes were harvested from C57BL/6
mice and plated in a 96-well collagen plate at 30,000 cells per well. For the first 24 hours
after plating, hepatocytes were cultured in 100 uL of Lonza Hepatocyte Plating media.
For comparison of LNP transfection in different media, the media was switched to either
100 uL of Lonza maintenance media or 100 uL of DMEM without FBS. LNPs were
prepared as previously described by mixing 10 uL of LNP solution with 10 uL of eGFP
mRNA solution. The 20 uL LNP:mRNA solution was then added to wells containing
plated hepatocytes and 80 uL of media. Twenty-four hours after adding LNPs, phase
contrast and fluorescent images were taken of the hepatocytes. Transfection efficiency
was calculated as the ratio of GFP positive cells to total cells. LNP delivery to primary
human hepatocytes followed the same procedure as the primary mouse hepatocytes.
Cryopreserved human hepatocytes were obtained from Lonza.
MTT Assays
Primary hepatocyte and Hepa 1-6 viability were measured 48 hours after seeding
and 24 hours after incubation with the LNPs. In primary mouse hepatocytes, the media
was replaced with 100 μL of fresh hepatocyte maintenance medium supplemented with
10 μL of 12 mM MTT stock solution (prepared by adding 1 ml of PBS to 5 mg of MTT).
The cells were then incubated for four hours at 37°C to create formazan crystals. The
produced formazan was dissolved by adding 100 μL of SDS-HCl solution and then
incubating for 4 hours at 37°C, and the absorbance was measured at 570 nm using a
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Biotek microplate reader. The same procedure was followed in Hepa 1-6 cells, but the
volumes were doubled to adjust for the 48-well plate format.
Measuring allele alterations using TIDE
Genomic DNA from transfected Hepa 1-6 cells was extracted using QuickExtract
DNA Extraction Solution (Lucigen) according to the manufacturer’s instructions. Briefly,
cells were harvested by adding 100 uL of trypsin and then pelleted by centrifuging at
1,000 g for five minutes. The pellet was then resuspended in 60 uL of QuickExtract
solution. PCR was then performed to amplify the target site in the Cypor locus. Primers
used for PCR amplification of target sites are listed in Table 5.2. PCR was performed
with OneTaq Hot Start DNA Polymerase (New England Biolabs) following the
manufacturer’s instructions for 30 cycles (94°C for 30 seconds; 94°C for 20 seconds;
59°C for 30 seconds; 68°C for 45 seconds). Amplicons were purified by Agencourt
AMPure XP beads (Beckman Coulter) and then subjected to Sanger sequencing (Eurofins
Genomics). Sanger sequence reads were uploaded to Tracking of Indels by
Decomposition (TIDE)21 and compared to a control sequence to quantify Cas9 generated
indels at the target site.
Table 6.2 PCR primers for amplification of Cypor for on-target TIDE analysis.
FWD
REV

GTTTGCGGGTGTTAGCTCTTC
AGTCTACTTCAGTCGCAGCC
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6.3 RESULTS
Six chalcogen-containing LNP formulations were tested for the delivery of eGFP
mRNA into HEK293 cells. The commercially available reagent, Lipofectamine 2000,
was used as a positive control for mRNA delivery. The cells were transfected at
increasing concentrations of LNP and mRNA, while the ratio of LNP to mRNA remained
10:1 (Figure 6.1A). Twenty-four hours after transfection, the percentage of fluorescent
cells was quantified by flow cytometry. Three of the LNP formulations (306-Se12, 306S10, and 113-O14) achieved higher transfection efficiencies (>40%) than the
Lipofectamine control. The other three formulations resulted in little or no fluorescence.
We also observed that increasing the concentration of LNPs in the well increased the
transfection efficiencies. The same LNP formulations were then used to deliver eGFP
mRNA in Hepa 1-6 cells. In our first experiment, no fluorescence was observed
following incubation with the LNP formulations. To improve transfection, Hepa 1-6 cells
were incubated with the nanoparticles in serum-free DMEM media. The removal of
serum significantly improved transfection efficiency (Figure 6.1B). The same three LNP
formulations that achieved high transfection efficiency in HEK293 cells also resulted in
increased transfection efficiency in Hepa 1-6 cells. Increasing the mass of LNP and
mRNA delivered to the cells to 4 μg LNP/0.4 μg mRNA resulted in nearly 100%
fluorescence in cells treated by the three formulations.
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Figure 6.1 Percentage of GFP+ cells 24 hours after transfection with six different
LNP formulations. (A) HEK293 cells (n=2). (B) Hepa 1-6 cells (n=2).
The three LNP formulations capable of transfecting HEK293 and Hepa 1-6 cells
were tested in freshly isolated mouse hepatocytes (Figure 6.2A). The tested
concentrations were 4 ug LNP/0.4 ug mRNA and 8 μg LNP/0.8 μg mRNA. To determine
if media containing serum would inhibit transfection, the LNPs were incubated with
hepatocytes in either DMEM media without FBS or Lonza hepatocyte maintenance
media. Hepatocytes cultured in Lonza media saw little or no fluorescence after incubation
with the LNPs except for cells treated with the 306-S10 LNP. Hepatocytes treated with
this formulation at 8 μg LNP/0.8 μg mRNA had 50% GFP positive cells (Figure 6.2). For
hepatocytes cultured in DMEM without FBS, low transfection rates were observed using
the 306-Se12 and 306-S10 LNP formulations. Cells treated with the 113-014 formulation
had transfection efficiencies close to 60% with either the 4 μg LNP/0.4 μg mRNA or the
8 μg LNP/0.8 μg mRNA treatment (Figure 6.2B). In subsequent experiments, hepatocytes
were incubated with LNPs in serum-free DMEM.
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Figure 6.2 Media comparison for LNP delivery of eGFP mRNA into primary
mouse hepatocytes. (A) Phase contrast and GFP fluorescent images of freshly
isolated mouse hepatocytes. (B) Percentage of GFP+ primary mouse hepatocytes 24
hours after transfection following supplementing Lonza maintenance media with
LNPs (n=1). (C) Percentage of GFP+ primary mouse hepatocytes 24 hours after
transfection in serum-free DMEM media supplemented with LNPs (n=1).
In the next experiment, we tested GFP mRNA delivery to freshly isolated mouse
hepatocytes with LNP concentrations ranging from 2 μg to 10 μg. Twenty-four hours
after transfection, viability was estimated using MTT assays. At 2 and 4 μg, the
Lipofectamine 2000 had higher transfection efficiency than the chalcogen containing
LNPs. Transfection efficiency with Lipofectamine declined drastically (<10%) at 6 μg of
LNP, and hepatocytes showed little or no fluorescence at higher concentrations. In
contrast, at 6 μg, transfection efficiency was higher with the LNP formulations 306-S10
and 113-O14. The highest transfection efficiency was achieved with 6 μg of LNP 113-
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O14 complexed to 0.6 μg of eGFP mRNA. At 10 μg of LNP, transfection efficiency
declined to <10% for both formulations. For the 306-Se12 formulation, the average
transfection efficiency was <10% for all tested concentrations. MTT analysis showed that
viability was higher for hepatocytes transfected with the chalcogen containing LNPs than
for cells treated with Lipofectamine. Of the three tested formulations, 113-O14 produced
the highest transfection rate while keeping cell viability above 60%. Based on this study,
the 113-O14 nanoparticle is an ideal candidate for delivering Cas9 mRNA into primary
hepatocytes.

Figure 6.3 LNP-mediated delivery of eGFP mRNA into freshly isolated mouse
hepatocytes. (A) Phase contrast and GFP fluorescent images of freshly isolated
mouse hepatocytes 24 hours after supplementing media with nanoparticles. (B)
Percentage of GFP+ mouse hepatocytes 24 hours after transfection (n=2). (C)
Viability normalized to untransfected control as determined by MTT assay performed
24 hours after transfection (n=2).
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We repeated the LNP comparison experiment in primary human hepatocytes
(Figure 6.4). Transfection efficiency was lower than 10% for hepatocytes treated with
Lipofectamine 2000 regardless of the concentration. The highest transfection efficiencies
were obtained with 6 μg of 306-Se12 and 4 μg of 113-O14 (46.0% and 45.6%,
respectively). The 306-S10 LNP typically had lower transfection efficiencies than the
other two formulations. Interestingly, the 306-Se12 LNP had much higher transfection
efficiencies in human hepatocytes than in mouse hepatocytes. MTT analysis showed that
viability was lower than 20% for human hepatocytes treated with Lipofectamine. In
contrast, the viability for hepatocytes treated with bioreducible LNPs was typically
between 30-40%, with hepatocytes treated with 8 μg of 306-Se12 having viability higher
than 60% (Figure 6.4B). Viability for the human hepatocytes was typically lower than the
mouse hepatocytes

Figure 6.4 LNP-mediated delivery of eGFP mRNA into primary human
hepatocytes. (A) Percentage of GFP+ mouse hepatocytes 24 hours after transfection
(n=2). (B) Viability normalized to untransfected control as determined by MTT assay
performed 24 hours after transfection (n=2).
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We then tested the 113-O14 LNP for delivery of Cas9 mRNA and Cyportargeting sgRNA into Hepa 1-6 cells (Figure 6.5). In the previous experiment with Hepa
1-6 cells, 4 μg of LNP complexed with 0.4 μg of mRNA was sufficient for greater than
90% transfection of Hepa 1-6 cells. For delivery of sgRNA and Cas9 mRNA, 4 μg of
113-O14 LNP were complexed varying amounts of mRNA and sgRNA. The mass of
mRNA and sgRNA complexed with the LNPs ranged from 0.1 μg to 0.24 μg, and we
tested various ratios of mRNA to sgRNA. DNA was extracted three days after
supplementing media with LNPs complexed to Cas9 mRNA and prepared for Sanger
sequencing. Indel analysis of the sequences indicated that little to no (<4%) gene-editing
occurred at the Cypor locus (Figure 6.5A). MTT results from the nanoparticle delivery
found that all treated samples had viability greater than 50% (Figure 6.5B).
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Figure 6.5 Delivery of LNP 113-O14 with Cas9 mRNA and Cypor-targeting
sgRNA. (A) Indels for Hepa 1-6 cells treated with 4 μg of LNP complexed with
varying concentrations of Cas9 mRNA and Cypor-targeting sgRNA (n=1). (B)
Viability normalized to untransfected control as determined by MTT assay performed
24 hours after supplementing media with LNPs (n=1).
To improve LNP delivery of Cas9 mRNA into Hepa 1-6 cells, we tested higher
concentrations of LNP complexed with RNA (Figure 6.6). The LNP:mRNA:sgRNA ratio
was maintained at 10:0.5:0.5, and LNP concentrations from 8 to 20 μg were delivered to
Hepa 1-6 cells. One well was treated with 6 μg of LNP complexed with 0.6 μg of eGFP
mRNA to confirm successful transfection of cells. Cells transfected with the eGFP
mRNA had a transfection efficiency of 54.7%. On-target indels for cells treated with
Cas9 mRNA were quantified using TIDE analysis. Hepa 1-6 cells treated with 8 μg and
12 μg of LNPs had comparable indel frequencies (16.4% and 17.5% indels) at the Cypor
target site (Figure 6.6A). Cells treated at higher concentrations did not have detectable
levels of indels. After treatment, viability for cells with 8 μg and 12 μg of LNPs was
comparable (63.7% and 61.8% viability) (Figure 6.6B). Viability in Hepa 1-6 cells
declined after increasing LNP concentrations. For cells treated with 16 μg of LNPs,
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viability was 53.6%, and viability decreased further to 42.1% after treatment with 20 μg
of LNPs.

Figure 6.6 Cas9-mediated gene editing in Hepa 1-6 cells. (A) On-target indels for
Hepa 1-6 cells treated with 113-O14 LNP complexed with Cas9 mRNA and Cyportargeting sgRNA (n = 2). (B) Viability normalized to untransfected control as
determined by MTT assay performed 24 hours after supplementing media with LNPs
(n = 2). Mock refers to samples treated with 6 μg of LNP and 0.6 μg of eGFP mRNA.
6.4 DISCUSSION
Lipid nanoparticles have been extensively studied for the transport of gene
therapy components8,22–24. Because of their strong safety profile, LNPs are a promising
candidate for delivering Cas9 for therapeutic gene editing. Obstacles such as low
transfection6–8, non-specific delivery9, and high toxicity in commercially available
reagents13 limit clinical translation of lipid-mediated delivery of Cas9 for therapeutic
gene editing. In this chapter, we investigated chalcogen-containing bioreducible LNPs for
the delivery of mRNA in cell lines and primary mouse hepatocytes. We identified three
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formulations (306-Se12, 306-S10, and 113-O14) that could deliver eGFP mRNA into
HEK293 and Hepa 1-6 cells at transfection efficiencies higher than the commercially
available reagent. We achieved transfection efficiencies greater than 40% in primary
mouse and human hepatocytes. This was higher than in primary hepatocytes treated with
Lipofectamine. In addition, viability analysis by MTT assays indicates that these LNPs
are less toxic to mouse and human hepatocytes than Lipofectamine.
Although the nanoparticle formulation 113-O14 achieved high transfection
efficiencies with eGFP mRNA in cell lines and primary hepatocytes, only low levels of
gene editing were observed when complexed with Cas9 mRNA and delivered to Hepa 16 cells. This indicates LNP-mediated delivery of GFP mRNA is not fully representative
of the delivery of Cas9 mRNA. We observed less than 20% gene editing activity in Hepa
1-6 cells treated with the 113-O14 formulation. This is much lower than desired for
therapeutic genome editing. Previous studies in mice have shown modest gene editing in
liver tissue after injection with bioreducible LNPs14,15. These studies investigated
different formulations than those in our research but still contained the basic structure of
an amine head group and an acrylic tail. Increasing the concentration of Cas9 mRNA in
the ratio may improve editing efficiency. Alternatively, the two other LNP formulations
that showed high transfection efficiency in hepatocytes could be investigated for Cas9
delivery.
6.5 CONCLUSION
We identified three bioreducible LNP formulations that can transfect cell lines
with eGFP mRNA at higher transfection efficiencies than commercially available
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Lipofectamine 2000. In primary mouse hepatocytes, we showed that for improved LNP
uptake requires cells to be cultured in serum-free medium. Two of the formulations had
better transfection with eGFP mRNA and higher viability than Lipofectamine in freshly
isolated mouse hepatocytes. All the formulations had higher transfection and viability in
human hepatocytes than Lipofectamine. Transfection of Hepa 1-6 cells with the 113-O14
LNP complexed to Cas9 mRNA and Cypor-targeting sgRNA resulted in low levels of
gene editing. Further optimization of bioreducible LNP formulations are necessary for
improved gene editing.
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CHAPTER 7
CONCLUSIONS AND RECOMMENDATIONS FOR FUTURE STUDIES
7.1 CONCLUSIONS
Safe and effective delivery of CRISPR-Cas9 nucleases into hepatocytes remains
an obstacle for developing liver-target gene therapies. Preclinical studies have reported
successful CRISPR-Cas9-mediated gene editing using AAVs in animal models of human
IMDs of the liver. However, AAVs are associated with safety concerns such as
immunogenicity risks1–4 and integration into Cas9 on- and off-target sites.5,6. The overall
goal of this research was to develop and optimize a nonviral method for the efficient
delivery of CRISPR-Cas9 into primary hepatocytes for genome editing. We show that
nonviral delivery of Cas9 into hepatocytes has strong potential for therapeutic gene
editing applications.
In the first aim of this study, we demonstrated that electroporation of Cas9 into
primary hepatocytes results in effective and rapid gene editing. We verified that our
sgRNA designs for targeting mouse and human HPD could achieve high levels of indels.
We examined different forms of Cas9 expression and found that Cas9 RNPs were more
efficient for gene editing than Cas9 mRNA or pDNA. We also examined the viability and
functionality of electroporated hepatocytes and found primary human hepatocytes had
high (>60%) viability following electroporation.
For the second aim of this research, we investigated chemically-modified sgRNA
for enhancing Cas9 gene editing and examined off-target editing by different forms of
Cas9 expression. We electroporated Hepa 1-6 cells and primary mouse hepatocytes with
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Cas9 proteins complexed to sgRNAs containing a 2'-O-methyl group and a
3’phosphorothioate linkage. While these additions significantly increased on-target
editing in Hepa 1-6 cells, no significant improvement was seen in primary mouse
hepatocytes. In contrast, previous studies found that chemically modified sgRNAs were
necessary to achieve high levels of editing in CD34+ hematopoietic stem and progenitor
cells and human T cells7,8. To determine if Cas9 expression influenced off-target editing,
we delivered Cas9 pDNA, mRNA, and RNPs to hepatocytes and examined editing at ten
potential off-target sites. We identified one off-target site, OF3, with high levels of
indels. Hepatocytes treated with Cas9 mRNA had high levels of editing at this site, while
cells treated with the RNP had reduced levels of editing. In addition, we electroporated
cells with the HiFi Cas9 variant that previous studies have shown to reduce off-target
editing in primary human cells9–11. We saw a slight reduction in off-target editing with
this variant of Cas9 compared to wild-type Cas9 RNP.
In the third aim of this study, we screened LNP formulations for transfection of
primary hepatocytes with mRNA. We identified three bioreducible LNP formulations
that could transfect the cell lines HEK293 and Hepa 1-6 with eGFP mRNA at higher
transfection efficiencies than the commercially available Lipofectamine. We also
demonstrated that transfection in mouse hepatocytes with chalcogen-containing LNPs is
improved in the presence of serum-free media. In mouse hepatocytes, two formulations
(113-O14 and 306-S10) had higher transfection efficiency than the commercial reagent.
Viability was also improved compared to hepatocytes transfected with Lipofectamine. In
human hepatocytes, we observed that all three tested formulations had improved
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transfection and viability compared to the commercial reagent. Initial experiments with
delivering Cas9 mRNA complexed to the 113-O14 LNP resulted in no gene editing.
Increasing the LNP and Cas9 mRNA concentrations did achieve ~20% on-target gene
editing in Hepa 1-6 cells.
7.2 RECOMMENDATIONS FOR FUTURE STUDIES
We achieved high levels of gene editing in primary hepatocytes following
electroporation-mediated delivery of Hpd-targeting Cas9 RNPs. Future research should
evaluate if hepatocytes electroporated under these conditions can engraft and repopulate
the liver of Fah deficient mice. Viability for electroporated mouse hepatocytes was less
than 60%, posing an obstacle for engraftment. Studies have indicated that adding Mg2+ to
the electroporation buffer can improve cell viability following electroporation12. Future
studies should consider optimizing the electroporation buffer to enhance cell viability.
NGS analysis indicated that most edits introduced at the target site were frameshift
mutations, potentially knocking out the expression of Hpd. Protein expression could be
measured by western blot analysis to confirm knockout of Hpd further. Electroporated
hepatocytes should be transplanted into a Fah-/- mouse model to establish that
electroporated cells are capable of engrafting onto the liver and have a therapeutic effect.
We demonstrated that adding a 2’-O-methyl group and a 3’phosphorothioate
linkage to the sgRNA is unnecessary to achieve high gene editing levels in primary
mouse hepatocytes. Future research should consider comparing unmodified and
chemically modified sgRNA in primary human hepatocytes, as this study only evaluated
mouse hepatocytes. Other modifications to the sgRNA should also be investigated in
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hepatocytes. For example, increasing the length of the crRNA has been shown to enhance
Cas editing efficiency13,14. Future studies should also assess if chemically modified
sgRNAs influence on- and off-target editing. One study has indicated that adding a 2’-Omethyl group to the sgRNA is correlated with increased toxicity in U2OS cells15.
Viability assays such as MTT or albumin could be performed on hepatocytes treated with
chemically modified sgRNAs to determine if they are toxic.
In this study, we examined off-target editing at ten sites with sequences highly
similar to the sequence located in the Hpd locus. Future research should expand the
number of off-target sites to be more exhaustive. Future studies should also examine offtarget editing in the human genome when using the HPD-targeting sgRNA. Wholegenome sequencing (WGS) should also be considered for identifying unexpected offtarget effects of Cas9.
Future studies with the bioreducible LNPs should screen more formulations for
Cas9 delivery into cells. In this study, we observed that the LNPs effectively delivered
eGFP mRNA into cell lines and primary hepatocytes. However, the LNP with the highest
transfection rate in primary hepatocytes only achieved low levels of gene editing when
used to deliver Cas9 mRNA. The nucleotide length of the Cas9 mRNA is over 4,500
nucleotides, much larger than eGFP mRNA, which is only 996 nucleotides. The 113-O14
LNP may not be able to carry cargo larger than the eGFP mRNA into cells. LNP toxicity
is a significant concern, and we showed that viability in human hepatocytes was often
reduced to less than 40% of untransfected cells. We incubated hepatocytes with LNPs for
24 hours before changing media. Toxicity may be reduced by lowering the incubation
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time with the LNPs. LNPs should be incubated with hepatocytes at varying times (such
as six, eight, and twelve hours), and transfection efficiency and viability should be
compared to determine if there is an optimal time for LNP incubation. Lastly, the work in
this chapter only covers in vitro transfection in primary hepatocytes. Direct
administration of LNPs into an animal model is necessary to characterize their efficacy in
vivo. This animal study should measure transfection efficiency by delivery of GFP,
hepatoxicity by AST and ALT measurements, and gene editing by sequencing of liver
tissue.
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Appendix A
Supplementary Tables for Aim 2.2
Table A-1 Deep sequencing output for Cas9 treated Hepa 1-6 cells (Figure 5.1). An
experiment refers to a biological sample. %ReadsWithIndels and #ReadsTotal are the
averages of two replicates per experiment.
Experiment 1
Target

Treatment

%ReadsWithIndels

ON

Cas9 mRNA

49.0645

OF1

Cas9 mRNA

OF2

Experiment 2

#ReadsTotal

Experiment 3

%ReadsWithIndels

#ReadsTotal

%ReadsWithIndels

#ReadsTotal

91

94.9375

184

82.17

129

0.106

2967

0.7105

2186

3.44

3439

Cas9 mRNA

0.534

2325

0.4845

9834

2.38

2102

OF3

Cas9 mRNA

5.108

7372

40.3695

523

6.225

3350

ON

Cas9 WT RNP

61.838

153

88.448

360.5

94.455

118

OF1

Cas9 WT RNP

0.1325

2067

0.4095

2217.5

3.36

2795

OF2

Cas9 WT RNP

0.495

2489

0.409

10420.5

2.505

1655

OF3

Cas9 WT RNP

0.8635

4372

12.1215

1480

11.41

2479

ON

Cas9 HiFi RNP

67.8335

111

91.552

154

95.4

113

OF1

Cas9 HiFi RNP

0.026

3180

0

2912

2.945

2811

OF2

Cas9 HiFi RNP

0.418

5320

0.231

10073

2.585

1657

OF3

Cas9 HiFi RNP

0.1855

6691

1.283

3154.5

20.965

2361

ON

pmax GFP

18.379

876

5.621

676

1.97

152

OF1

pmax GFP

0.101

3979

0.033

2994

3.15

2383

OF2

pmax GFP

0.386

6986

0.219

7749

2.39

1592

OF3

pmax GFP

0.265

9426

0.088

2283

3.1

2545

152

Table A-2 Deep sequencing output for Cas9 treated cryopreserved primary mouse
hepatocytes (Figure 5.2). An experiment refers to a biological sample.
%ReadsWithIndels and #ReadsTotal are the averages of two replicates per experiment.
Experiment 1
Target

Treatment

%ReadsWithIndels

ON

Cas9 mRNA

25.421

OF1

Cas9 mRNA

OF2

Cas9 mRNA

OF3
ON

Experiment 2

#ReadsTotal

Experiment 3

%ReadsWithIndels

#ReadsTotal

%ReadsWithIndels

#ReadsTotal

275

86.1815

148

100

35

0.3265

2614

1.285

2201

6.39

153

0.5365

2440

0.73

6525

0.285

5791

Cas9 mRNA

2.129

3089

47.74

1427

43.6005

1297

Cas9 WT RNP

60.347

124

86.2855

60

65.5845

37

OF1

Cas9 WT RNP

0.233

2849

1.356

1063

0.827

1484

OF2

Cas9 WT RNP

0.315

2816

0.3305

7293

0.2415

8825

OF3

Cas9 WT RNP

10.174

2928

22.1385

5228

17.74

1835

ON

Cas9 HiFi RNP

54.775

333

97.3135

111

92.263

113

OF1

Cas9 HiFi RNP

0.32365

136

0.1615

2267

0.6865

1255

OF2

Cas9 HiFi RNP

0.346

5773

0.3545

9337

0.42

7804

OF3

Cas9 HiFi RNP

4.5545

2651

1.255

3499

2.951

3245

ON

pmax GFP

9.979

471

17.708

96

5.152

127

OF1

pmax GFP

0.13

2308

0

819

2.033

246

OF2

pmax GFP

0.331

1209

0.292

10613

0.282

7087

OF3

pmax GFP

0.222

3601

0.207

4351

0.276

2533

153

Table A-3 Deep sequencing output for Cas9 treated freshly isolated primary mouse
hepatocytes (Figure 5.2). An experiment refers to a biological sample.
%ReadsWithIndels and #ReadsTotal are the averages of two replicates per experiment.
Experiment 1
Target

Treatment

Experiment 2

Experiment 3

%ReadsWithIndels

#ReadsTotal

%ReadsWithIndels

#ReadsTotal

%ReadsWithIndels

#ReadsTotal

ON

Cas9 mRNA

100.000

75

90.340

42

50.000

2

OF1

Cas9 mRNA

0.800

2

2.985

3154

2.590

4001

OF2

Cas9 mRNA

1.085

2

2.215

519

2.335

464

OF3

Cas9 mRNA

5.000

3

5.110

972

3.555

754

OF4

Cas9 mRNA

1.085

2

2.150

972

2.275

470

OF5

Cas9 mRNA

0.520

2

2.190

939

1.675

645

OF6

Cas9 mRNA

2.975

2

2.830

908

2.695

829

OF7

Cas9 mRNA

0.945

1

3.025

1490

3.195

1234

OF8

Cas9 mRNA

2.330

0

3.410

86

5.510

46

OF9

Cas9 mRNA

0.655

2

2.385

695

2.235

528

OF10

Cas9 mRNA

0.575

2

1.925

763

2.415

676

ON

WT RNP

75.000

5

85.610

28

100.000

4

OF1

WT RNP

1.840

7412

2.175

5574

1.240

1578

OF2

WT RNP

1.625

735

2.160

1000

1.960

255

OF3

WT RNP

3.185

1187

5.895

1372

7.250

401

OF4

WT RNP

1.670

1051

1.860

1834

0.895

419

OF5

WT RNP

1.795

1643

1.715

1741

1.790

503

OF6

WT RNP

2.425

2519

2.615

2151

1.480

627

OF7

WT RNP

1.400

2122

1.770

2579

0.975

590

OF8

WT RNP

0.365

120

1.675

176

4.690

32

OF9

WT RNP

2.130

1924

2.080

1510

2.040

392

OF10

WT RNP

1.820

3202

2.075

2025

1.510

498

ON

eGFP mRNA

37.500

5

29.165

8

50.000

6

OF1

eGFP mRNA

1.830

6390

2.325

3805

2.520

3850

OF2

eGFP mRNA

1.825

600

2.040

367

2.075

417

OF3

eGFP mRNA

1.780

1883

1.730

1162

2.470

1001

OF4

eGFP mRNA

1.625

1468

2.080

969

2.855

653

OF5

eGFP mRNA

1.680

1815

1.810

831

2.800

718

OF6

eGFP mRNA

2.200

2894

2.490

1647

2.025

1087

OF7

eGFP mRNA

1.370

1602

2.130

1316

3.420

1245

OF8

eGFP mRNA

1.430

100

1.705

61

5.010

50

154

OF9

eGFP mRNA

2.255

1916

2.595

929

1.755

641

OF10

eGFP mRNA

1.500

3493

1.610

1183

2.120

792

155

